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Nanostructured calcium phosphate (NanoCaPs) particles are biocompatible and non-toxic 
bioceramics widely studied owing to their structural and compositional similarity to the 
mineralized tissue architecture of native bone. They are therefore considered as an ideal choice 
for gene delivery applications in bone tissue engineering. However, NanoCaPs are typically 
characterized by variable transfection, short shelf life due to particle aggregation, and difficulties 
associated with endosomal escape. The objectives of this dissertation were therefore crafted to 
develop strategies to circumvent, if not eliminate, some of the limitations that have previously 
stymied the success of NanoCaPs as a non-viral gene delivery vector for bone tissue engineering 
applications.  
A modified version of NanoCaPs containing critical concentration of silicate ions substitutions 
were synthesized, aptly called NanoSiCaPs. Fundamental understanding of the influence of 
silicate ion substitutions in the NanoCaPs lattice structure was conducted using various materials 
characterization techniques. In-vitro transfection results indicated, a two-fold increase in 
transfection levels exhibited by NanoSiCaPs, owing to the enhanced dissolution kinetics and 
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ability to limit particle aggregation. Subsequently, two different strategies were developed to 
achieve scaffold mediated gene delivery via generation of plasmid DNA bound to NanoSiCaPs 
(NanoSiCaPs complexes, NC). First, a novel and simple coating methodology was developed 
using NCs adsorbed on Ti-surfaces coated with polyelectrolyte. Surface characterization results 
indicated successful generation of the nanoceramic coating on the Ti-surfaces. Additionally, it 
was demonstrated that the Ti-polyelectrolyte-NC assemblies contribute to surface mediated gene 
transfection, without eliciting any cytotoxicity. Second, a lyophilization technique was 
developed that enabled long-term storage of the NCs under ambient conditions, without inducing 
either a significant change in particle size or loss in gene transfection efficiency. Subsequently, a 
3-D gene delivery system comprising fibrin hydrogels and lyophilized NCs was developed. In-
vitro transfection results indicated that gene expression mediated via synthesized gels can be 
meticulously controlled by modulating the amounts of fibrinogen and NCs utilized in the 
synthesis of the gels. In conclusion, the studies demonstrate creation of next generation NanoCaP 
vectors, NCs and their implementation in the development of 3-D scaffolds serving as effective 
gene delivery agents as well as functional scaffolds for bone tissue repair and regeneration.  
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1.0  INTRODUCTION 
1.1 BONE TISSUE 
Bone tissue is a dynamic, highly vascularized tissue that provides essential mechanical and 
structural support to the body. Due to its high degree of vascularization, bone tissue is constantly 
undergoing phases of resorption (via osteoclasts) and reformation (via osteoblasts) [1]. Bone 
healing involves a complex set of events encompassing many genetic and molecular triggers, 
morphogens, signaling molecules, and transcriptional regulators that act in concert during 
specific stages of bone tissue remodeling process [2]. However, healing capacity of bone in some 
situations might be limited or insufficient to heal large bone defects. Without medical 
intervention, the response of the body is relatively limited and is mainly restricted to repair 
processes, and repair in most scenarios does not lead to the restoration of normal structure and 
function [3]. Therefore, biomaterial-based tissue engineering strategies for regeneration of 
damaged bone tissues are being developed and evaluated that may enable the repair of tissues 
with high complexity, while avoiding excessive inflammation and an immune response to the 
medical implants [3].  
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1.2 TISSUE ENGINEERING AND REGENERATIVE MEDICINE 
Tissue engineering is a multifaceted discipline combining the fields of materials science, 
bioengineering, pharmacy, life sciences and medicine towards the development of biological 
substitute materials, systems and devices, with a common goal to induce regeneration of 
damaged or diseased organs within the body [4-6]. The field of tissue engineering thus ranges 
from controlling cellular responses to material implants, manipulating the healing micro 
environment for tissue growth and implant integration, to developing a fundamental understating 
of many biological processes that guide tissue regeneration [4, 7]. Traditional tissue engineering 
approaches involved use of either or both, a biomaterial scaffold that allowed cell infiltration, 
proliferation and subsequent regeneration; or cell therapy, where autologous or allogenic cells  
are implanted at defect sites to stimulate repair [5, 7]. 
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Figure 1.1. Tissue engineering strategies 
 
 
More recently, an innovative approach has evolved that involves incorporation of 
regenerative stimuli into biomaterial scaffolds to enhance the regenerative response to host cells, 
termed as in-situ tissue engineering [7]. This approach involves incorporation of growth factors 
[8, 9], cytokines [10, 11], genetic factors [12, 13] in the biomaterial scaffold to induce specific 
cellular response for host tissue regeneration (Figure 1.1).  
1.2.1 Bone tissue engineering 
In the U.S., more than 15 million people suffer from bone fractures annually.  Defects may occur 
due to  injuries, infections, tumors, or degenerative diseases [3]. Delayed healing or non-union 
occurs in 5-10% of all fractures and 20% of high impact fractures [14]. This impaired healing is 
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caused by the body’s inability to regenerate the bone, and complication due to poor healing leads 
to prolonged hospitalizations and result in high health care costs [3, 14]. In addition, non-union 
fractures especially those in anatomical locations suffering from a low blood supply such as the 
distal radius or scaphoid bone, do not have optimal therapies [14]. Therefore, bone regeneration 
therapies continue to require optimization and improvement because many of the skeletal 
disorders remain untreated. Current treatment of bone injuries typically involves using 
autologous or allogenic bone grafting methods but have several limitations, such as donor site 
morbidity, risk of infection, and disease transmission [15]. Naturally derived or synthetic bone 
graft substitutes made of metals, ceramics and polymers are also clinically employed as potential 
treatment options to improve the overall bone healing outcomes, but lack the osteogenic capacity 
of auto-grafts [16]. In addition to excellent biocompatibility and biomechanical properties, 
successful bone healing outcome using synthetic grafts also depends on other critical factors 
such as favorable osteoconduction, osteoinduction, and vascularization [16]. Therefore, control 
over cellular and tissue interaction with biomaterials is garnering importance. Moreover, these 
biomaterials are implanted more frequently in geriatric population suffering from other major 
health problems, which interfere with the natural healing response around implants [15]. 
Successful healing of fractures requires integration of engineered tissue with surrounding host 
tissues and involves combined input from signaling generated by intercellular communications, 
cell-matrix interactions, and growth factors [7]. Therefore, design of biomaterial scaffold loaded 
with therapeutics that allow for spatio-temporal release within the defect site thus remains to be 
one of the imperative clinical need in the field of bone tissue engineering.  
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1.2.2 Gene therapy for bone tissue engineering 
Popular bone tissue engineering strategies involve the delivery of external factors such as 
therapeutic proteins or genes to promote the repair or regeneration of tissues [3]. Protein-based 
therapies utilize cytokines or growth factors to directly target the wound site [15]. On the other 
hand, gene therapy exploits the advantage of the intrinsic production capability of proteins by the 
resident cells at or near the target site after successful delivery and expression of genes of interest 
[14]. Therefore, delivering genes can encode the therapeutic cytokines or growth factors, and can 
achieve the same effect as protein therapy. Moreover, the production of therapeutic proteins via 
its genetic counterpart can potentially be more sustained than administering the proteins locally 
that tend to denature rapidly, thus limiting its activity once delivered into the body [7]. Due to 
short half-lives and rapid degradation, supraphysiological levels of proteins (in milligrams) are 
administered for relevant clinical outcomes which may result in side effects [17, 18], for example 
high doses of recombinant BMP-2 protein can result in soft tissue swelling, radiculitis and 
ectopic bone formation [19].  On the other hand the delivery of genes will not be hindered by its 
stability or short half-lives issues since the carrier will ensure that the genetic information is well 
protected by the binding, condensation and packaging ability of the carrier [20]. In this respect, 
gene therapy appears to be more attractive, reliable and cost effective than protein therapy [14]. 
However, it is a well-known fact that the main obstacle toward achieving successful gene 
therapy is not the identification of therapeutic genes, but rather, the lack of a suitable gene 
delivery technique that is non-toxic, non-immunogenic and efficient [21].   
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1.3 GENE DELIVERY 
Gene delivery is a technique used to introduce genetic information (DNA, RNA) to cells 
directing the synthesis of a specific protein. Typically, the “genetic information” or exogenous 
gene categorized as nucleic acid payloads can be divided into two groups based on their 
mechanism of action: (i) genome-editing systems like clustered regularly interspaced short 
palindromic repeats (CRISPR-Cas9), Zinc finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs); and (ii) transiently acting such as plasmid DNA (pDNA), 
messenger RNA (mRNA), micro RNA (miRNA), small interfering RNA (siRNA) or small 
hairpin RNAs (shRNA), and antisense oligonucleotides (AONs) [21]. Genome editing systems 
are commonly used in treatment of genetic disorders through permanent genetic modification in 
the human genome through gene correction, disruption, and whole gene-insertion [21]. Recently, 
several CRISPR based techniques have been developed and approved by FDA for immune-
oncology and oncology therapies and others are likely to be approved within few years to treat 
retinal degeneration and hemophilia [22]. On the other hand, transiently acting systems are 
commonly employed for tissue engineering application since the expression of gene is required 
for a short period for regeneration of the damaged tissue [14].  
Among numerous nucleic acid payloads, the most common transient expression dependent 
systems comprise circular, double-standard DNA constructs, termed as plasmids or plasmid 
DNA (pDNA) [21]. These plasmids contain several basic components to drive gene expression 
such as origin of replication, promoter, gene of interest, terminator, regulatory signals, antibiotic 
resistance gene, and the remaining base pairs termed as plasmid back bone [7].  
Once inside the cells, pDNA is transcribed to mRNA in the nucleus of the cells following 
which gene of interest is subsequently translated to protein in the cytoplasm of the cells [7]. Use 
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of pDNA in gene therapy is common due to its rapid clearance from the body thereby reducing 
off-target side effects and cytotoxicity [23, 24]. Moreover, the cost of production of pDNA in 
large amounts with high purity for clinical application is relatively low as compared to 
production of recombinant proteins [25, 26]. However, due to the various biological 
characteristics of  super-coiled pDNA, which include its large size (∼3000 kDa) and net negative 
zeta-potentials of -30 to -70 mV owing to its phosphodiester back-bone [27, 28], plasmids are 
prevented from readily crossing the plasma membrane [29]. They are thus, considered inefficient 
for gene transfection. Physical methods of introducing pDNA to cells such as DNA injection [30, 
31], gene gun administration [32, 33], electroporation [31, 34-36] have been developed but these 
methods are not widely used due to its feasibility and potential to cause damage to cells. 
Targeted and efficient delivery of pDNA therefore requires a more sophisticated delivery system 
that is discussed in the following section.  
1.3.1 Gene delivery vectors 
Vectors for gene delivery typically comprised of viral and non-viral types. Viral vectors are 
widely used in gene therapy applications, with approximately 70% of clinical trials carried out so 
far for gene therapy treatments utilized viral vectors such as lentiviruses, adeno-viruses, adeno-
associated viruses and retroviruses [37]. Viral vectors are generally preferred for gene therapy 
applications since they are capable of transduction of non-dividing cells (lentiviruses) and 
inserting genetic payload in the host chromosome (retroviruses), driving long term gene 
expression [38]. Although viral vectors are extremely efficient and capable of delivering genetic 
payloads to cells with high specificity, they do suffer from several inherent shortcomings such as 
small capacity for packaging DNA, safety concerns (such as insertional mutagenesis and 
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associated carcinogenesis), and difficulty associated with production of large number of viruses 
[27, 37, 39-43]. Nevertheless, development of viral vectors in recent years has substantially 
advanced the gene-delivery technology and lead to development of Food and Drug 
Administration (FDA)-approved gene therapeutics, Kymriah and Yescarta, both anti-CD19 
chimeric antigen receptor (CAR) T-cell therapies for B-cell cancers [44]. Approval of Kymriah 
and Yescarta has led to renewed excitement within the field with the hope that these therapies 
will pave way for approval of more gene therapeutics. It seems likely that treatment of genetic 
disorders will be approachable with gene editing systems like CRISPR/Cas9, using viral vectors 
where a long-term expression is needed to combat a persistent condition [38, 44]. However, for 
tissue engineering applications where an initial stimulation or transient expression is enough to 
promote cell proliferation and differentiation, viral vectors are not necessary [7, 45]. In addition, 
for the purpose of bone tissue engineering, transient gene expression-the type of expression 
achieved using non-viral vectors- is desirable because it limits the amount of newly formed bone 
and decreases the chances for bone malformation [14]. 
Recent advances in materials science and nanobiotechnology has led to the development 
of next generation synthetic, non-viral vectors that exhibit low immunogenicity and toxicity 
compared to the viral counterparts [46]. Non-viral vectors also permit high genetic payloads and 
incur low cost of production on a large scale [47, 48]. Examples of common non-viral vectors 
include lipids (liposomal or non-liposomal), and cationic polymers [28, 49-59], branched 
cationic polymers termed as dendrimers, and co-precipitates of purified DNA and CaP 
(hydroxyapatite) [60-69]. Numerous synthetic transfection reagents have been commercialized 
for in vitro gene transfer, for example the liposomal transfection reagents Lipofectamine 
(Invitrogen, USA), the non-liposomal lipid transfection reagent FuGENE HD (Roche, 
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Switzerland), the dendrimer-based transfection reagent Superfect (Qiagen, USA), the 
polyethyleneimine (PEI)-based transfection reagent, jetPEI (Polypus-transfection, USA) and the 
calcium phosphate transfection reagent, Profection (Promega, USA) [70]. In addition, some non-
viral transfection reagents have recently been optimized for in vivo gene transfer and 
commercialized (e.g. in vivo jet PEI) [39]. Among the non-viral systems, lipid and polymer-
based vectors display higher transfection efficiency over other systems, but their use in tissue 
engineering applications is still limited for their associated toxicity [27].  Ideally, for tissue 
engineering applications scaffolds are loaded with non-viral vectors with or without cells and are 
expected to allow for spatio-temporal release of vectors. Given that non-viral systems face 
challenges in the successfully delivery of pDNA to cells, scaffolds are generally loaded with 
substantial amounts of non-viral vectors to achieve desired therapeutic effect. However, use of 
lipid and polymer based non-viral vectors in large amounts is limited due to their potential side 
effects to the surrounding tissue [39]. Therefore, safer and more efficient non-viral systems are 
still being sought.  
1.4 CALCIUM PHOSPHATE BASED GENE DELIVERY SYSTEMS 
Among all the various non-viral gene delivery systems currently under investigation [62, 71-81], 
calcium phosphate (CaP) mediated gene transfection is considered to be an attractive option due 
to its ability for in-vitro transfection of a wide variety of mammalian cells with little or no 
toxicity [82]. Furthermore, nanostructured calcium phosphate biomaterials are of special interest 
for bone tissue engineering applications as they share chemical/crystallographic similarities to 
inorganic components of bone [83]. Several CaP phases exist and among those hydroxyapatite 
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(HA), Ca10(PO4)6 (OH)2; Ca/P = 1.67) and tricalcium phosphate (TCP, Ca3(PO4)2, Ca/P = 1.5) 
are the most widely used due to their close structural similarity to the mineralized matrix of 
natural bone [84-89].  Among these, HA phase is also one of the most stable phases that can be 
generated under physiological conditions. As such, it has been the model system that has been 
widely studied thus far for non-viral gene delivery applications [27].   
Hydroxyapatite (HA) can be either pure or calcium-deficient. Pure HA, Ca10(PO4)6(OH)2, 
has the stoichiometric Ca to P ratio of 1.67 [68]. Stoichiometric HA can be prepared 
hydrothermally by solid-state reactions at either 375 °C or > 900 °C or by sintering apatite 
precipitated from very basic conditions (pH > 11) above 900 °C [68]. However, these synthesis 
methods are not suitable for biological applications since they require the use of such high 
temperatures and non-physiological conditions. As a result, aqueous based approaches have been 
developed to synthesize HA. These approaches yield calcium deficient or nonstoichiometric 
Ca/P (i.e. Ca/P < 1.67) [68]. Typically, for gene delivery applications, a solution comprised of 
CaCl2 and pDNA is added drop wise to an equal volume of a HEPES buffered phosphate 
solution (pH ~ near physiological) comprised of HEPES, NaCl and Na2HPO4. Conventional CaP 
synthesis procedures involved manual mixing of these precursor solutions that typically results in 
complexes with variable particle sizes that tend to aggregate rapidly, which when implemented 
in gene transfection experiments often result in low and variable transfection efficiencies.  
Particle aggregation is unfavorable since it ultimately reduces the ability of these 
complexes to be internalized by cells, thus limiting the gene transfection ability of the CaP 
vectors [67]. Optimal calcium and phosphate concentrations in the precursor solutions, which 
determine the Ca/P ratio and controlled mixing of the two solutions, can produce particles within 
the size range of 50-100nm [67, 68]. Smaller sized particles are also known to exhibit a higher 
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specific surface area, since specific area is defined as 3/rρ, where r is the radius of the particle 
and ρ is the density of the particle (assuming a spherical morphology). Radius being inversely 
proportional to the specific surface area implies that smaller particles have higher surface area 
thereby capable of higher DNA loading during the precipitation of CaP particles. Therefore, 
efforts have been made to optimize the synthesis technique to generate nanostructured calcium 
phosphate pDNA complexes, aptly called NanoCaPs.  
1.4.1 Nanostructured calcium phosphate pDNA complexes (NanoCaPs) 
To overcome the problems associated with existing manual method of mixing precursor solution 
for generation of CaP particles, Olton et al reported a novel synthesis technique for generation of 
consistent, nano-sized, mono-dispersed CaP-pDNA particles, termed as NanoCaPs [67]. The 
authors demonstrated the significance of optimizing both the stoichiometry (Ca/P ratio) of the 
CaP particles as well as the mode in which the calcium and phosphate precursor solutions are 
mixed. NanoCaPs synthesized using Ca/P ratio of 130 and a controlled mixing flow rate of 
13.4µl/s exhibited transfection efficiencies ~25 fold greater than conventional HA using 
literature methods [67, 69]. However, to become clinically relevant NanoCaP vectors must better 
tolerate the challenges of a physiological environment that impede the clinical translation of this 
gene delivery technology. There are numerous extracellular and intracellular barriers that must 
be overcome to achieve efficient gene transfection, which are discussed in the following 
sections.  
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1.5 BARRIERS TO SUCCESSFUL NANOCAPS MEDIATED GENE DELIVERY 
Irrespective of the type of non-viral vector employed, a gene-delivery vector must navigate 
through numerous barriers to achieve efficient gene transfection as shown in Figure 1.2. They are 
broadly categorized into: (1) extracellular barriers; (2) intracellular barriers [21]. Besides these 
barriers there are manufacturing considerations that also play a critical role in determining the 
feasibility of clinical application of the gene delivery vector.  
1.5.1 Extracellular barriers 
There are numerous extracellular barriers a non-viral gene delivery vector faces, however the 
significance of those barriers depends on the route of administration of these vectors. For clinical 
translation, a key issue to be considered in practice, is whether administration should be 
intravenous or direct injection to the target tissue. Direct injection lacks specificity and requires 
repeated administration of vectors at the target site, whereas intravenous delivery of vectors faces 
several barriers for the application to be effective [27]. One of the main factors limiting the 
effectiveness of intravenous delivery of non-viral gene delivery vectors is the colloidal instability 
of these complexes in the extracellular space [21, 27]. Colloidal instability arises due to the high 
ionic strength in the extracellular space, and the presence of serum components. In addition to 
colloidal instability, non-viral vectors are prone to rapid clearance by non-parenchymal cells, 
rapid degradation of the DNA by plasma nucleases, accumulation or deposition in organs such as 
the skin, lung, and intestines [27]. Additionally, even in the case of direct delivery, the 
complexes may suffer from inflammation, immune response, and the rapid degradation of the 
DNA by plasma nucleases, before it could enter the target cells [27]. Therefore, introduction of 
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scaffold materials is one way of overcoming such hurdles in systemic and local delivery of 
vectors, as scaffold would provide protection to the vector complex, and ensure stable and 
controlled release of the complexes over time. 
1.5.2 Intracellular barriers 
Once the gene delivery vector reaches the cell surface after overcoming all the extracellular 
barriers, it must gain entry to the cell through endocytosis ( Figure 1.2). Olton et al demonstrated 
that cellular uptake of NanoCaPs is mediated by both clathrin- and caveolae- dependent 
endocytosis [66]. In general, CaP based vectors once inside the endosome compartments undergo 
acid-triggered dissolution (pH 6.0-6.5, early endosomal pH) that results in a massive proton 
influx creating an osmotic pressure across the endosomal membrane, followed by its rupture and 
finally release of pDNA from the vesicles in the cytosol for nuclear translocation [27].  
Therefore, changes in NanoCaPs dissolution kinetics to enable early release from endosomes 
thereby escaping lysosomal degradation pathway can help overcoming one of the intracellular 
barriers. Additionally, pDNA once in the cytosol, must make its way into the nucleus of the cell 
via nuclear pore complex for the transcription of transgene [21]. It is currently accepted that non-
viral vectors heavily rely on cell division during which nuclear membrane breaks down and 
pDNA released from vectors is randomly incorporated in daughter nuclei. However, for non-
dividing cells, the presence of nuclear envelope poses a significant challenge [27]. In these 
instances, nuclear localization sequences (NLS) are incorporated into the vector-DNA complexes 
or in the pDNA backbone to direct the plasmid to the nucleus via active transport [90-92]. 
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 Figure 1.2. Barriers to non-viral gene delivery. 
Reproduced with permission [21]. 
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1.6 STRATEGIES TO OVERCOME BARRIERS FOR NANOCAPS MEDIATED 
GENE DELIVERY 
The following section will lay down the fundamentals behind the strategies employed for current 
research work that will circumvent, if not eliminate, some of the limitations that have previously 
stymied the success of NanoCaPs as a gene delivery vector for bone tissue engineering 
applications.  
1.6.1 Ionic substitution in NanoCaPs 
CaP particles have an inherent propensity to aggregate rapidly with time in dispersing media due 
to low surface charge (around -20mV) [93]. Rejman et al. have reported that particles <100 nm 
are readily endocytosed by cells [94]. The expected uncontrolled growth and aggregation of CaP 
particles however, expectedly results in lower levels of gene expression.  There are, however 
reports on stabilizing the growth of CaP particles by coating with lipid [95], adsorption of 
chitosan on growing CaP aggregates to prevent particle aggregation and provide stability to the 
gene delivery vector [96]. On the other hand, there are reports in literature showing cationic 
substitution of magnesium and strontium, and anionic substitution of carbonate and fluoride into 
the calcium phosphate-based gene delivery systems contributing to enhanced transfection 
efficiency [97-102]. This increase in transfection efficiency due to substitution with cations or 
anions is attributed to the possible reduction in particle aggregation and faster dissolution of the 
endocytosed particles. Notably, one of the most crucial intracellular barrier for CaP based 
vectors is escape from endosomes and release of the functional plasmid DNA in the cytosol 
[103]. Plasmid DNA that escapes endosomes effectively, escaping lysosomal degradation, 
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successfully make their way to the nucleus through the nuclear pore complex or get distributed 
during cell division [27]. 
Since escaping endosomes effectively is crucial for the CaP based vectors, putatively, this 
makes it even more pertinent to fine tune the dissolution characteristics of nanostructured CaPs 
(NanoCaPs) by incorporation of various cations and anions, as reported in the literature [99, 104-
107]. Furthermore, the motivation for ionic substitution of CaPs arises from the fact that the 
natural bone mineral is composed of not only calcium and phosphate moieties, but also 
carbonate, sodium, magnesium, potassium, zinc, barium, copper, aluminum, iron, fluoride, 
chloride, and silicon ions [108, 109]. Thus, investigating the influence of ionic substitution on 
NanoCaPs mediated gene delivery would be an efficient strategy to alter its materials properties 
thereby enhancing its transfection abilities. 
1.6.2 Freeze drying of NanoCaPs 
While ionic substitution of NanoCaPs will influence the material properties of the vector 
complex and potentially increase the transfection efficiency when used in aqueous suspension, 
long term storage of these particles in aqueous medium will lead to particle aggregation and 
ultimately resulting in poor transfection results. Furthermore, to be clinically relevant, it is ideal 
to develop a technique that will allow for long-term storage of NanoCaPs under ambient 
conditions, which would also enable shipment of pre-made NanoCaPs, while maintaining its 
transfection abilities. Lyophilization is a very attractive way to achieve dried pharmaceuticals in 
general and DNA-based formulations [110]. However, the freeze-drying process involves two 
stresses, freezing and drying, that are known to be damaging to macromolecules and 
nanoparticulate structures, unless appropriate stabilizers are used [111, 112]. 
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Lyoprotectants are additives which serve as stabilizing agents during freeze-drying. 
These additives effectively stabilize vector complexes due to their ability to both replace water as 
well as their ability to form stable glasses [110, 113]. Notably, several studies have shown use of 
monosaccharides, disaccharides, oligosaccharides and polysaccharides as a stabilizing agent for 
freeze drying of polyplexes and lipoplexes vectors [113-117]. Thus, use of a stabilizing agent 
will serve to maintain the native environment of the NanoCaPs complexes in the lyophilized 
state, thus minimizing the particle aggregation while maintaining efficient levels of gene 
expression. Changes to the materials properties of NanoCaPs and development of technique that 
allows for long term storage of the particles would enhance the gene transfection prowess of 
these vectors, however for bone tissue engineering application their incorporation in scaffolds is 
necessary. 
1.6.3 Surface mediated gene delivery 
Segmental bone defects are critical sized bone defects that are not amenable to healing by the 
inherent regenerative capacity of bone [118] due to the large defect size. Treatment of segmental 
bone defects is at present typically accomplished using autologous or allogenic bone grafting 
methods [118]. Naturally derived or synthetic bone graft substitutes made of metals, ceramics 
and polymers are also clinically employed as potential treatment options to improve the overall 
healing outcomes but lack the osteogenic capacity of auto-grafts. In addition to excellent 
biocompatibility and biomechanical properties, successful bone healing outcome using synthetic 
biomaterials also depends on other critical factors such as favorable osteoconduction, 
osteoinduction, and vascularization [3]. Additionally, the surface of implanted biomaterials is in 
direct contact with the host bone and soft tissue, and plays a critical role in determining the 
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biocompatibility, functional compatibility and tissue integration of implants [119]. Therefore, 
control over cellular response towards biomaterial surfaces is garnering importance. Moreover, 
these biomaterials are implanted more frequently in geriatric population suffering from other 
major health problems, which interfere with the natural healing response around implants. Thus, 
it is necessary for implant surfaces to evoke a controlled cellular and tissue interfacial response 
for better tissue integration of biomedical implants.  
Various strategies have been employed to improve osseointegration property of implants 
namely, florid modification, micro-arc oxidation treatment, electrolytic and heat treatment as 
well as alkali treatment, etc [120]. Coating of implants with a thin layer of calcium phosphate has 
also proven to be an effective approach to providing the base material with good 
biocompatibility and good osteoconductivity owing to its similarity with native bone structure 
[121]. Interestingly, numerous studies have focused on creating calcium phosphate composite 
layers immobilizing DNA on the surfaces of base materials [122-124]. These resulting composite 
layers are endowed with useful characteristic of both osteoconductive bioceramics and 
transfection reagents; they thus provide a biocompatible surface to support cell attachment, 
spreading, and proliferation, and can stimulate the cell effectively via surface-mediated gene 
transfer. Therefore, development of a user-friendly technique that allows adsorption of 
NanoCaPs on surfaces of biomaterials commonly utilized for bone tissue engineering would 
further expand the applications of NanoCaPs as a non-viral gene delivery technology. 
Techniques commonly employed for surface mediated gene delivery and their limitations are 
discussed in Chapter 4.0 .  
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1.6.4 Three-dimensional polymeric scaffolds for gene delivery 
Gene expression mediated via non-viral gene delivery is transient in nature as the delivered 
pDNA does not integrate in the host genome and is randomly distributed during cell division, 
and/or degraded over time. Therefore, to be able to attain a long-term therapeutic effect, the 
sustained expression of the transgene should be implemented. Surface mediated gene transfer, as 
discussed in the previous section, is one of the ways of achieving scaffold mediated gene 
delivery. However, release of vector complexes from the bulk of the scaffold material still 
presents a significant challenge. The proposed solution lies in the utilization of three-dimensional 
(3-D) scaffolds to accomplish what the NanoCaPs alone cannot achieve. Typically, polymeric, 
biodegradable, and highly porous biomimetic extracellular matrix materials are engineered to 
mimic the bone microstructure comprised of crystalline/amorphous CaP and polymer/CaP 
composite with or without growth factors [125-127]. Hydrogels are a class of biomaterials that 
have a great scaffolding potential in many tissue engineering applications owing to their tissue-
like water content, high biocompatibility in general, mechanical properties that parallel the 
properties of soft tissues, efficient transport of nutrients and waste, powerful ability to uniformly 
encapsulate cells, growth factors and genetic material, and ability to be injected as a liquid that 
gels in-situ [15, 128-130]. Furthermore, injectable hydrogel formulations can be utilized to 
infiltrate porous metallic and ceramic biomaterials commonly used for bone tissue engineering. 
Naturally derived polymers, such as chitosan, gelatin, collagen, and fibrin are commonly 
employed for scaffold design to support bone formation because of their biocompatibility and 
biodegradability [15, 127, 131]. 
Hydrogels, as a 3-D scaffold is intended to serve multitude of purposes. First, the 3-D 
scaffold serves as templates for the infiltration, attachment, and proliferation of cells and 
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subsequent tissue formation in three dimensions. Second, the scaffold acts as a protective shield 
to prevent the embedded factors from the harsh external environment such as low pH and 
enzyme degradation, thereby overcoming extracellular barriers. Third, the scaffold provides the 
sustained release of embedded factors over time to allow long-term therapeutic effects. Finally, 
in the case of NanoCaPs, by entrapping and distributing NanoCaPs complexes over a 3-D 
volume, the aggregation of NanoCaPs complexes can potentially be reduced or eliminated since 
the interactions between the individual NanoCaPs particles are less likely to occur.  
Therefore, with all the strategies discussed to circumvent the limitations faced by 
NanoCaPs mediated gene transfection, we are now prepared to present the overall goal of this 
dissertation.  
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2.0  SPECIFIC AIMS 
The overall goal of this dissertation is to create new class of NanoCaPs gene delivery vectors via 
ionic substitution. We hypothesize that alteration of materials properties of NanoCaPs will 
confer superior transfection abilities on the synthesized nanoparticles. Additionally, by 
developing methodologies that enable sustained gene expression achieved through creation of 
modified NanoCaPs complexes would help in creation of functional scaffolds for bone tissue 
repair and regeneration. Accordingly, three specific aims have been formulated.  
2.1 SPECFIC AIM 1 
Synthesize silicate substituted calcium phosphate nanoparticles (NanoSiCaPs), perform 
materials characterization, and assess in-vitro gene delivery efficiency of the substituted 
NanoSiCaPs system.  A modified version of NanoCaPs will be developed by substituting 
different amounts of silicate in lieu of phosphate through aqueous precipitation method. The 
synthesized silicate substituted NanoCaPs/HA (NanoSiCaPs/SiHA) will be characterized using 
different materials characterization techniques. We hypothesize that substitution of silicate in 
NanoCaPs will alter its material properties thereby affecting its transfection ability and pDNA 
binding efficiency. Therefore, we would also investigate the in-vitro gene delivery efficiency of 
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synthesized NanoSiCaPs, in addition to pDNA binding efficiency, and morphology of the 
nanoparticles.  
2.2 SPECIFIC AIM 2 
Synthesize polyelectrolyte NanoSiCaPs complex assemblies (PNA) on titanium substrates 
for surface mediated gene delivery. A technique will be developed to adsorb NanoSiCaPs 
complexes on Titanium (Ti) substrates by dip coating method. We hypothesize that using the 
electrostatic interaction between negatively charged NanoSiCaPs complexes and positively 
charged polymer coated Ti-surfaces, we can obtain a nanoceramic coating that can achieve 
surface mediated gene transfection. Surface composition and microstructure of the coated Ti 
surfaces will be assessed using different materials characterization techniques. The substrates 
will be assessed for their in-vitro transfection efficiency, cell attachment and viability.  
2.3 SPECIFIC AIM 3 
Formulate and synthesize a 3-D gene delivery system using fibrin hydrogels to encapsulate 
lyophilized NanoSiCaPs complexes, for achieving increased stability and longer shelf life. 
The lyophilization technique would be developed that allow long term storage of NanoSiCaPs 
complexes. We hypothesize that by determining optimum conditions for freeze-drying of 
NanoSiCaPs complexes, long-term storage of these complexes is possible while maintaining 
particle stability and transfection efficiency. Additionally, incorporation of lyophilized 
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NanoSiCaPs in fibrin gels would further limit particle aggregation and provide sustained gene 
expression. Optimum conditions for lyophilization of NanoSiCaPs will be determined. A fibrin 
gene delivery system with NanoSiCaPs will be synthesized and the role of different components 
utilized in the synthesis of this gene delivery system will be assessed.  
 
In order to distinguish between the calcium phosphate used in different applications, the 
use of CaPs as gene delivery vectors will henceforth be referred to as NanoCaPs or NanoSiCaPs 
while calcium phosphate in the bulk will be referred to as HA or SiHA throughout the text of this 
dissertation to avoid any confusion. Additionally, NanoCaPs or NanoSiCaPs with pDNA will be 
referred to as NanoCaPs or NanoSiCaPs complexes.  
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3.0  SYNTHESIS AND CHARACTERIZATION OF SILICATE SUBSITITUTED 
CALCIUM PHOPSHATE NANOPARTICLES FOR NON-VIRAL GENE DELIVERY 
3.1 INTRODUCTION 
Nano-structured ceramic particles, particularly, nano-particles of calcium phosphate (CaP) 
remain an attractive option among the various types of non-viral gene delivery vectors studied 
because of their safety, biocompatibility, biodegradability, and ease of handling as well as their 
adsorptive capacity for DNA.  However, they are still not accepted as the ideal choice for gene 
delivery because of the known difficulties associated with endosomal escape, and the partial 
protection of DNA from nuclease degradation that automatically results in lower levels of gene 
expression [132]. The inherent propensity of CaP particles to aggregate rapidly with time in 
dispersing media is also another determining factor for achieving efficient gene delivery [133]. 
Rejman et al. have reported that particles <100 nm are readily endocytosed by cells[94]. The 
expected uncontrolled growth and aggregation of CaP particles however, expectedly results in 
lower levels of gene expression. Therefore, this chapter examines the influence of ionic 
substitution to overcome the limitations stated above to enhance the transfection efficiency of 
NanoCaPs.  
Motivation for ionic substitution of NanoCaPs further arises from the fact that the natural 
bone mineral is composed of not only calcium and phosphate moieties, but also carbonate, 
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sodium, magnesium, potassium, zinc, barium, copper, aluminum, iron, fluoride, chloride, and 
silicon ions[108, 134]. Recent work in the literature has also shown that incorporation of silicon 
into hydroxyapatite (HA) results in changes to the properties of HA such as the lattice parameter, 
morphology, crystallinity, surface chemistry, kinetics of dissolution, etc. [134-137]. Despite the 
fact that silicon substituted HA is considered to be a bioactive bone substitute due to its enhanced 
solubility [135, 136], no attempt to date, to the best of our knowledge, has been made to evaluate 
the potential of silicon substituted CaPs (NanoSiCaPs) as a gene delivery vector. This therefore 
sets the stage for an ideal opportunity to explore silicon substituted CaPs as a potential gene 
delivery vector and explore further whether these properties of modified HA would prove 
beneficial particularly, for non-viral gene delivery.  
In a previous study, our group has already reported a novel simple synthesis approach 
that generates nanocrystalline HA particles (NanoCaPs) approximately 50-100 nm in size under 
physiological conditions that were efficient at both binding and condensing the pDNA [67]. 
Furthermore, the results of transfection indicate their superior response compared to other 
commercially available non-viral transfection agents [69]. The current work therefore aims to 
demonstrate further improvement resulting in dramatic enhancement of the transgene expression 
by the inclusion of a critical concentration of silicate species into the NanoCaPs system to 
generate silicate substituted NanoCaPs that is aptly termed as NanoSiCaPs (Figure 3.1).  
The focus of the current work presented here is therefore to exploit the aforementioned 
properties of silicate substituted HA (SiHA) to improve the gene delivery prowess, by 
incorporating different levels of silicate anions into the nanostructured CaPs (NanoCaP) to 
accordingly form the NanoSiCaPs system. Different analytical techniques were further utilized to 
understand the role of silicate substitution on the structure, morphology, dissolution properties 
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and phase change of the substituted HA phase. The impact of silicate substitution on the 
transfection efficiency of NanoCaPs complexes was further assessed using flow cytometry while 
also assessing the binding capability of NanoSiCaPs compared to un-substituted NanoCaPs.  
Results of all these studies are presented and discussed in this chapter. 
 
 
 
 
Figure 3.1. Schematic representation of synthesis of NanoSiCaPs complexes.  
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3.2 MATERIALS AND METHODS  
3.2.1 Materials 
Calcium chloride (CaCl2⋅2H2O), tri-sodium phosphate do-decahydrate (Na3PO4⋅12H2O), sodium 
chloride (NaCl), Bis-Tris, and dextrose were purchased from Fisher Scientific (Pittsburgh, PA). 
Potassium chloride (KCl) was purchased from Sigma Aldrich (St. Louis, MO). Sodium 
hydroxide (NaOH) was purchased from Mallinckrodt Baker Inc. (Phillipsburg, NJ). Sodium 
metasilicate (Na2SiO3⋅5H2O) was purchased from Alfa Aesar (Ward Hill, MA). HEPES and 
ethidium bromide (EtBr) were obtained from EMD Chemicals (Gibbstown, NJ). Reporter 
plasmid, gWizTM GFP (Green Fluorescent Protein), were purchased from Aldevron LLC (Fargo, 
ND). All of the reagents were used as received without further modification or purification. 
3.2.2 Synthesis of as-prepared bulk HA and SiHA 
The precursors used for synthesizing as-prepared HA were CaCl2⋅2H2O, Na3PO4⋅12H2O, and 
NaOH, based on the following chemical reaction which has also been reported by us earlier 
[138]:  
10CaCl2 + 6Na3PO4 + 2NaOH → Ca10 (PO4)6(OH)2 + 20NaCl (Equation 3-1) 
 
 
The molar ratio of Ca/P was fixed at 1.67, and correspondingly, stoichiometric amounts 
of OH were added to maintain the HA phase and composition. To summarize the synthesis, 5.8 g 
of CaCl2⋅2H2O was dissolved in 100 ml of double-distilled water (ddH2O) with a conductivity of 
18.2 Ω/cm to form solution A. 9.12 g of Na3PO4⋅12H2O and 0.36 g of NaOH were dissolved in 
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another 100 ml of ddH2O to form solution B. Solution A was then added into solution B drop by 
drop under constant stirring at room temperature. The solution mixture quickly turns turbid, and 
the formation of a white precipitate is instantly observed. The white precipitate was collected 
using a Beckman J2-MC centrifuge (Beckman Coulter Inc, Fullerton, CA) at 2000 rpm and the 
supernatant was accordingly discarded. The white precipitate was then re-suspended into ddH2O 
to rinse away the NaCl salt, obtained as a byproduct. The washing and centrifugation steps were 
repeated at least 3 times to ensure the complete removal of NaCl. The white precipitate obtained 
was then air dried in an oven (Isotemp, Fisher Scientific, Pittsburgh, PA) at 70°C for 72 hours 
and ground to a fine powder before conducting any further materials characterization. 
Silicate substituted HA, or SiHA referred henceforth, was also synthesized in a similar 
fashion. Various amounts of silicate (Si) were substituted into HA based on the molar ratio of 
Ca/ (P+Si) (SiHA). The precursors used for synthesizing SiHA were once again, CaCl2⋅2H2O, 
Na3PO4⋅12H2O, NaOH, while Na2SiO3⋅5H2O served as the Si precursor for generating SiHA. 
The ratios of Ca/ (P+Si) were fixed at 1.67, and correspondingly, stoichiometric amounts of OH- 
were also added to maintain the HA composition. The proposed chemical reactions for SiHA is: 
10 CaCl2 + (6-x) Na3PO4 + x Na2SiO3 + (2-x) NaOH + x/2O2 → Ca10 (PO4)6-x (SiO4) 
x(OH)2-x + (20-2x) NaCl + xCl2  (Equation 3-2) 
 
 
Where, x = number of moles of substituted silicate and the percentage of molar 
substitution is determined by the site substitution of PO43- (% mol substitution =x/6*100). Note 
that all the reactions followed for synthesizing SiHA only considered the physical site 
substitution of SiO44- ions into any of the available PO43- or OH- sites, while any potential charge 
imbalances that may arise due to the substitutions of anions with the different ionic charges of 
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trivalent or pentavalent P and tetravalent Si were disregarded throughout this study. Table 1 
summarizes the amount (mol.) and weight (wt.) of Ca, P and Si precursors used for generating 
each of the SiHA powder prepared with x equal to 0, 0.5, 1, 2, 3, 4, or 5 hereafter designated HA, 
8.3SiHA, 16.6SiHA, 33.3SiHA, 50SiHA, 66.6SiHA and 83.3SiHA, respectively. Herein, we 
follow the convention for representing the silicate substitution in mol %, and not on a weight 
percent (wt.%) basis.  
 
 
Table 1: Precursor composition of calcium, phosphorus and silicon for synthesis of HA and SiHA. 
 
  
 
 
3.2.3 Synthesis of pDNA loaded NanoCaPs and Si-substituted NanoCaPs 
The synthesis of the pDNA loaded NanoCaPs and Si- substituted NanoCaPs (NanoSiCaPs) is 
very much dependent on the Ca/P ratios of the corresponding Ca and P precursors. To maintain 
the nano-scale size range of the substituted and un-substituted calcium phosphate (CaP) particles, 
the ratios of Ca/P and Ca/(P+Si) were set at 130 instead of the 1.67 ratio normally used for 
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synthesizing HA in the bulk. The ratio of 130 was selected based on the Ca/P ratio that resulted 
in formation of nanostructured HA, while also displaying the most optimal transfection levels 
from our previously published report [139]. Herein, the reported nanostructured HA particles are 
designated as NanoCaPs complexes (containing pDNA) for un substituted samples and 
correspondingly, following the nomenclature mentioned above, NanoSiCaPs complexes for 
silicate substituted samples with different amounts of silicate substitution being 8.3, 16.6, 33.3, 
50, 66.6 and 83.3 NanoSiCaPs (% mol) as shown in Table 1. The synthesis of un-substituted 
NanoCaPs complexes and NanoSiCaPs complexes were adapted from the synthesis of HA and 
SiHA described above. Briefly, 15.53 μl of 2M CaCl2 and 6.35 μl of plasmid DNA (1mg/ml, 
gWiz GFP) were diluted in 103.2 μl of ddH2O to form the solution A (125μl total). An equal 
volume (125μl) of solution B containing HEPES-buffered solution (280 mM NaCl, 10 mM KCl, 
12 mM dextrose, and 50 mMHEPES) and 1.5 mM Na3PO4 was also prepared. The HEPES-
buffered solution was intended to maintain the pH of the precursors at 7.5. The precursors of 
NanoSiCaPs contained the same solution A, and the solution B used for NanoSiCaPs also 
contained the HEPES-buffered solution and a mixture of 1.5 mM of (Na3PO4 + Na2SiO3) for 
silicate, respectively with the appropriate adjustments needed for the addition of the silicate ion. 
The molar ratios of Ca/P and Ca/(P+Si) as mentioned above, was also maintained at 130 for all 
the samples synthesized. The un-substituted NanoCaPs complexes and NanoSiCaPs complexes 
were then synthesized using a Harvard Apparatus PHD 2000 Infuse/Withdraw syringe pump 
(Holliston, MA) to introduce and mix the two solutions in a controlled drop wise fashion to 
generate the desired homogeneous dispersion of the NanoCaPs and NanoSiCaPs in solution 
similar to our published reports. Hence, solution A was added drop by drop into solution B at an 
addition rate of 13.4μl/s while solution B was vortexed at 500 rpm (Figure 3.1). The addition rate 
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was also selected following our previously published report [139]. Accordingly, the as-
synthesized NanoCaPs complexes and NanoSiCaPs complexes in suspension were used for in-
vitro transfection, particle size characterization and pDNA binding experiments. 
3.2.4 Materials characterization  
X-ray Diffraction (XRD) patterns for both the as-prepared bulk HA and SiHA powders (8.3, 
16.6, 33.3, 50, 66.6 and 83.3SiHA) were collected using a Philips X’Pert PRO X-ray diffraction 
system (PAN Analytical, Westborough, MA) with CuKα radiation (λ = 1.5418Å). The 
diffractometer was operated at 45 kV and 40 mA and scanned over the 2θ range of 20-60°. The 
step size was 0.03 and the time per step was 50.17 s for each X-ray run. The XRD patterns were 
generated using the Philips X’PertData Collector and analyzed using the Philips 
X’PertHighscore Plus software. All the XRD patterns were verified and compared to existing 
library of references from the Joint Committee on Powder Diffraction Standards (JCPDS). 
Fourier-transform Infrared Spectroscopy (FTIR) was used to identify the various functional 
groups present in the as-prepared HA and different SiHA powders. FTIR spectra of the as-
prepared HA and silicate substituted SiHA samples were collected using the Nicolet 6700 
spectrophotometer (Thermo Electron Corporation) using a diamond ATR (Smart Orbit) Scanning 
electron microscopy (SEM) was used to observe the morphology of both, the as-prepared HA 
and SiHA samples. Powdered samples of as-prepared HA and 8.3SiHA, 50SiHA and 83.3SiHA 
were accordingly mounted onto double-sided carbon tapes and sputter coated with palladium 
using a Cressington sputter coater 108A (Cressington Scientific Instruments, Ltd, Watford, UK). 
The SEM images were taken on a Philips XL30 field emission gun SEM (Philips-XL30 FEG, 
Philips) and Energy Dispersive X-ray Analysis (EDAX) results were obtained using the built-in 
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EDAX system (EDX Genesis, EDAX Inc.). To measure the dissolution properties of HA and 
SiHA samples, ion release test was performed in Bis-Tris buffer at pH 7.2, pH 6.5 and pH 5.8, 
respectively. Bulk synthesized samples were used for the dissolution study, wherein 100mg of 
as-prepared HA, 8.3 SiHA, 50 SiHA and 83.3 SiHA was dispersed in 150ml of buffer at different 
pH and incubated at 37oC for 24 hours. 10ml of the Bis-Tris Buffer was taken for elemental 
analysis to be used for estimating the calcium ion concentration (n=3). Immediately after taking 
each aliquot, the samples were centrifuged at 7000rpm for 20 minutes to ensure separation of any 
residual solids. After centrifugation, the supernatant was carefully aspirated and stored at 4°C 
until elemental analysis was conducted. Spectroscopic elemental analysis was performed through 
inductively coupled plasma optical emission spectroscopy (ICP-OES, iCAP duo 6500 Thermo 
Fisher). The calcium ion concentrations were correspondingly measured for different samples 
using 0.2, 0.5, 1, 5, 10, 50 and 100 ppm standards. 
3.2.5 In-vitro experiments  
All cells were cultured in 75 cm2 flasks in a humidified incubator at 37oC in 5% CO2. NIH3T3 
cells were cultured with DMEM supplemented with 10% FBS and 1% P/S; and MDA-MB-231 
cells were cultured with EMEM supplemented with 10% FBS, 1% sodium pyruvate and 1% P/S. 
Cells were maintained to a sub-confluence state and were passaged at least twice a week. For the 
transient transfection experiments, the cells were seeded in 12-well plates at cell-density of about 
1.0 x 105 cells per well. The gWiz GFP was complexed with either NanoCaPs or silicate 
substituted NanoCaPs, i.e. NanoSiCaPs as described above in Section 2.2, and immediately 
transferred drop by drop into each well (n=3). The volume of the NanoCaPs-pDNA complexes 
or NanoSiCaPs-pDNA complexes added into each well was maintained at 81.5μl. The amount of 
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total pDNA complexed with each sample was 6.35μg, equivalent to 2.11μg per well. The 
NanoCaPs were incubated with the cells for 24 hours after which transfection efficiency was 
measured by counting the GFP positive cells using the Accuri C6 Flow Cytometer. Cells were 
allowed to incubate with NanoCaPs and NanoSiCaPs for 24 hours after which they were 
extracted from the well plates using 0.5% trypsin-EDTA solution. The cells were re-suspended 
in 400 μl PBS (pH of 7.4) and transferred to 15 mm tubes for flow cytometry. On the Accuri C6 
(Accuri Cytometers, Ann Arbor, MI) flow cytometer, the FLA-1 filter set corresponds to the 
GFP wavelengths. The cells were selected using a forward v/s side scatter plot from a sample of 
GFP negative cells serving as the control by using accordingly, cells transfected with void 
NanoCaPs (without plasmid DNA). This also gave us a filter for correcting the auto 
fluorescence. After filtering out the auto fluorescence, the ratio of GFP-positive to total number 
of cells was then obtained for each well (total of 5000 cells were counted for each sample). This 
ratio was subsequently used as a measure for calculating the transfection efficiency for the 
respective transfection agent.  
3.2.6 Plasmid DNA binding assay 
The extent of pDNA binding for particles synthesized was determined via Nanodrop 2000 
spectrophotometer (Thermo Fisher). 250 µl solutions of un-substituted NanoCaPs and 
NanoSiCaPs, loaded with pDNA as well as void, were prepared for each sample (n=3). Once 
synthesized, all the solutions were then centrifuged at 4°C for 10 minutes at 12,000g using a 
Mikro 200R ultracentrifuge (Andreas Hettich GmbH & Co.KG, Tuttlingen, Germany). 
Following centrifugation, the amount of unbound, non-precipitated DNA remaining in the 
supernatant of each solution was then quantified by measuring the optical density (OD) at 260 
 34 
nm using the NanoCaPs without pDNA as a blank. It was also verified that none of the 
supernatants absorbed at 320nm, since this would indicate that either not all of the precipitate 
was removed by centrifugation or that further precipitation occurred after centrifugation. The 
binding efficiencies were then determined using the following equation: 
E%= ([pDNA]o-[pDNA]f)/[pDNA]o x 100 (Equation 3-3) 
 
 
Where, [pDNA]o represented the concentration of pDNA added to the reaction mixture and 
[pDNA]f represented the concentration of the non-precipitated pDNA remaining in the 
supernatant.  
3.2.7 Transmission electron microscopy (TEM) of the synthesized NanoCaPs and 
NanoSiCaPs complexes 
The NanoCaPs complexes were prepared according to the aforementioned synthesis protocol 
(Section 2.2). One drop, approximately 5μl, of un-substituted NanoCaPs, 8.3, 50 and 83.3 
NanoSiCaPs complexes was then immediately added onto a carbon coated copper grid (Electron 
Microscopy Sciences, Hatfield, PA) and allowed to equilibrate for 3 min. The grids were then 
stained with 2% ACS grade uranyl acetate (Sigma Aldrich, St. Louis, MO), rinsed in 95% 
ethanol and allowed to air dry. Images were subsequently taken using a JEOL 1011 transmission 
electron microscope (TEM) (Tokyo, Japan) set to an accelerating voltage of 200 kV. 
3.2.8 Statistical analysis 
Statistical calculations were performed using the IBM SPSS Statistics 20 statistical analysis 
program. The data was analyzed to test for significant (p<0.05) mean differences on dissolution 
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properties, pDNA binding values and in vitro transfection efficiencies for both NIH3T3 and 
MDA-MB-231 cells across the various substituted nanoparticles using the one-way analyses of 
variance (ANOVA). Post hoc tests for pair-wise differences and identification of homogeneous 
subgroups were also all performed using the Tukey HSD procedures and discussed in the results 
section for the relevant groups. 
3.3 RESULTS 
3.3.1 Materials characterization 
XRD analysis of samples prepared in the bulk was performed to identify the crystalline phases 
present and to verify whether the substituted silicate species were incorporated into the HA 
lattice structure preserving the single-phase HA structure or phase separate out as a distinct and  
detached phase. The XRD patterns of HA, 8.3SiHA and 16.6SiHA contained peaks that matched 
with the standard diffraction pattern of HA (JCPDS 01-074-0565), with major peaks centered at 
2θ= 26.0˚ (hkl = 002 plane), 32.1˚ (112), 33.1˚ (300), and 34˚ (202) (Figure 3.2). XRD pattern of 
the as-prepared HA and the different silicate containing HA are shown in Figure 3.2b. No other 
phase was detected for all these samples although samples exhibit broad diffraction lines, which 
indicates low crystallinity and nano-crystalline state of the synthesized materials. With further 
increase in substitution to 33.3mol%, the XRD pattern becomes completely amorphous with no 
characteristic peaks of HA. The pattern for 50 SiHA, 66.6SiHA and 83.3SiHA however, in 
addition to the semi-amorphous phase, displayed characteristics of calcium silicate hydrate 
phases (Figure 3.3). Although the crystalline XRD peaks for 66.6SiHA and 83.3SiHA matches 
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with the 1.4-nm crystallite size of the tobermorite phase (Ca5Si6O16(OH)2.8H2O) of calcium 
silicate hydrate [140], no further attempts were however, made in this study to characterize the 
compositions and structures of the tobermorite and the amorphous phases. The XRD patterns 
thus indicate that for the amount of silicon, Si mol. % < 33.3 (or 0<x<1), the crystalline phase of 
the precipitates is HA and silicon can be incorporated into the apatite structure or amorphous 
phase or in both likely in the form of silicate species.  
 
 
 
 
Figure 3.2. X-ray diffraction patterns of as-prepared samples. 
(a) XRD patterns of standard HA, as-prepared HA and 8.3SiHA. Peaks were indexed based on the 
JCPDS #01-074-0565. (b) XRD patterns of as-prepared HA and SiHA with different silicon concentrations. 
XRD peaks of 16.6SiHA and 83.3SiHA were indexed based on JCPDS # 01-74-0565 and JCPDS # 00-029-
0331, respectively. 
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Figure 3.3. X-ray diffraction patterns of as-prepared 83.3SiHA and calcium silicate. 
XRD patterns showing comparison of 83.3SiHA with as-prepared CaSiO3 with standard hydrated 
calcium silicates. 
 
 
FTIR was therefore performed to identify the molecular groups present in the samples, which in 
conjunction with XRD, can be used to identify the crystalline and amorphous phases present in 
the samples. Figure 3.4a show the FTIR spectra for pure HA, as-prepared HA and 8.3SiHA. The 
FTIR spectrum of the as-prepared HA and 8.3SiHA exhibited bands characteristic of pure HA, 
including ν4(PO4) bands at 559 cm-1 and 599 cm-1, ν3(PO4) bands at 1017 cm-1and 1089 cm-1, 
ν1(PO4) band at 962 cm-1, OH- stretching band at 3571 cm-1  and OH- bending band at 631 cm-1 
[108, 138]. Other bands corresponding to HA were also observed, including bands for absorbed 
 38 
water at 1639 cm-1 and 3385 cm-1, and ν3 bands for carbonate CO32- at 1421 cm-1 and 1459 cm-1, 
and ν2bands for CO32- at 875 cm-1 that could be attributed to the incorporation of atmospheric 
CO2 into the sample. The presence of both absorbed water and CO32- has also been previously 
reported [136, 138, 141]. Few small additional bands not apparent in samples below 33.3 mol% 
substitution, were observed for 50SiHA, 66.6SiHA and 83.3SiHA (Figure 3.4b) at  ~980 cm-1 
which are attributed to Si-O stretching vibrations and group of bands near 500cm-1 that become 
apparent with increasing silicate concentration are an indication of calcium silicate hydrate 
phases[142], present as an amorphous phase as indicated by XRD results discussed above. 
Detection of these molecular vibrations via FTIR irrespective of the amorphous or crystalline 
state is a clear indicator that all of the silicates for low levels of substitution exhibited the HA 
phase.  
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Figure 3.4. FTIR spectra of as-prepared samples. 
(a) FTIR spectra of standard HA, as-preapred HA and 8.3SiHA. (b) FTIR spectra of standard HA 
and SiHA with different silicon concentrations. 
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Figure 3.5. SEM of as-prepared HA and SiHA samples. 
 (a) as-prepared HA, (b) 8.3SiHA, (c) 50SiHA and (d) 83.3SiHA 
 
 
SEM was then used to observe the morphology of the as-prepared HA and SiHA powders. Due 
to the semi-amorphous nature of the as-prepared samples, most of the samples appeared to 
comprise hard aggregates (Figure 3.5) showing no preferred or characteristic features of facets or 
platelet formation typical of the apatite structures. Hence, it was difficult to detect or distinguish 
any particular morphology of the particles. Visually, therefore there was also no secondary phase 
clearly observed in the SiHA samples. 
EDAX spectra collected on the samples considered for SEM analysis were used to verify 
the elemental composition of the samples. The EDAX spectrum obtained for the as-prepared HA 
powders showed peaks belonging to calcium (Ca) and phosphorus (P) indicating presence of 
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both elements, as well as small peaks for oxygen (O) (Figure 3.6). The presence of Ca, P, and O 
confirmed that the sample contained calcium phosphate. Figure 6 depicts the EDAX spectra for 
8.3SiHA, 50SiHA and 83.3SiHA, respectively. In addition to Ca, P, O peaks, a silicon (Si) peak 
was also detected in each of these samples. As anticipated, the 8.3SiHA sample exhibited a 
larger P peak than Si peak, while the 83.3SiHA sample showed the opposite, reflecting the initial 
amounts of P and Si in the precursor. The Ca/P molar ratio (1.57) of the as prepared HA powder 
was lower than the expected value of 1.67 based on the concentration of the starting precursors. 
Moreover, the ratio of Ca/(P+Si) decreases with increase in silicate substitution most likely due 
the formation of structural defects, substitution of other cations and anions, and the formation of 
secondary phases that have been observed in the XRD and FTIR discussed above. 
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Figure 3.6. EDAX spectra of as-prepared HA and SiHA samples. 
(a) as-prepared HA, (b) 8.3SiHA, (c) 50SiHA and (d) 83.3 SiHA 
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Figure 3.7. Dissolution kinetics of as-prepared HA and SiHA samples. 
ICP dissolution study of as-prepared HA and SiHA in BisTris buffer showing released ion 
concentration of calcium. The data were reported as mean ± SD (n=3). 
 
 
Dissolution characteristics of the as-prepared samples were evaluated in order to understand the 
effect of silicate substitution on HA dissolution at different pH. Accordingly, the as-prepared HA 
and SiHA samples were dispersed in Bis-Tris buffer and aliquots were taken at 24-hour time 
points. ICP-OES was then used to determine the calcium ion concentrations in the buffers at pH 
7.2, 6.5 and 5.8, respectively. ICP-OES measurements show that the silicate substituted samples 
released much higher levels of calcium than the as-prepared HA, and the dissolution profile of 
samples increased with higher amounts of silicate (Figure 3.7). It should also be noted that the 
dissolution increases with decreasing pH, as all the samples released higher amounts of calcium 
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ion in the increasing order of pH 5.8 > 6.5 > 7.2 (p<0.05).  This dissolution profile for the 
various silicate substitutions is clearly an important factor that will contribute to the in vitro 
transfection of these silicate substituted compositions that will be discussed in the following.  
3.3.2 In-vitro transfection results 
The flow cytometry results of GFP transfected MDA-MB-231 and NIH3T3 cells by NanoCaPs 
complexes and NanoSiCaPs complexes are shown in Figure 3.8. GFP Fluorescent results at 24 
hours post-transfection showed that both cell lines transfected with NanoCaPs, 8.3 NanoSiCaPs, 
and 16.6 NanoSiCaPs complexes exhibited the highest number of green-fluorescing cells. On the 
other hand, decrease in GFP expression with 66.6 NanoSiCaPs and 83.3 NanoSiCaPs complexes 
are observed indicating that very poor transfection is observed for these large silicate 
substitutions. For NIH-3T3cells (Figure 3.8) in particular, the transfection levels displayed a 
volcano trend as the anion substitution increased from 0 mol% (un-substituted NanoCaPs) up to 
83.3 mol% (83.3 NanoSiCaPs) with increased transfection levels observed for NanoCaPs 
corresponding to 8.3, 16.6, 33.3 and 50 Si (mol%) substitutions. The transfection results for both 
the cell lines showed a considerable increase in transfection levels for 8.3, 16.6 and 33.3 
NanoSiCaPs compared to the un-substituted NanoCaPs (p<0.05). For samples with 66.6 and 83.3 
Si (mol%) substitutions, the transfection levels however, began to drop by nearly 10-fold, to the 
point that the transfection levels practically became insignificant with more than 50% silicate 
substitution indicating the strong influence of incorporation of silicate ions into the HA structure 
on pDNA transfection. 
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Figure 3.8. Transfection efficiency of NanoCaPs and NanoSiCaPs complexes. 
Flow cytometry analysis (at 24hours) of GFP transfected MDA-MB-231 and NIH-3T3 cells by 
NanoCaPs and NanoSiCaPs complexes with different silicon concentrations. The control used for the flow 
analysis included GFP negative cells using cells transfected with void NanoCaPs (without pDNA). 
Transfection experiments were run in duplicates for each sample and repeated three times, n=6 (p<0.05). The 
data were reported as mean ± SD. Post hoc analysis of the transfection profile of NanoSiCaPs with NanoCaPs 
showed statistical significance (p<0.05), indicated by the asterisk (*). 
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3.3.3 Plasmid DNA binding analysis  
DNA loading efficiencies of NanoCaPs and NanoSiCaPs are shown in Figure 3.9. 8.3 
NanoSiCaPs were found to be capable of packaging 81% of total pDNA, similar to the control 
sample of un-substituted NanoCaPs (~82% of total pDNA), statistically not significant. 
However, as the amount of silicate substitution increased, the corresponding loading efficiency 
was observed to decline. In fact, for 66.6 and 83.3 NanoSiCaPs, only as much as 10-30% of 
pDNA was observed to be loaded onto the particles while most of the initial pDNA was observed 
to remain in the supernatant. This drastic decline in the pDNA loading efficiency in these 
samples therefore likely contributed to the poor transfection levels since the majority of the 
initial pDNA was unable to be bound to the NanoSiCaPs gene delivery carriers due to the likely 
presence of multiple phases as discussed above as well as the probable instability of these phases 
in the solid state causing the pDNA to remain largely in solution.  
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Figure 3.9. pDNA binding efficiency of NanoCaPs and NanoSiCaPs complexes. 
Samples were analysed in duplicates and repeated three times, n=6 (p<0.05).  The data were reported 
as mean ± SD. Post hoc analysis of pDNA binding efficiency of NanoCaPs, 8.3 NanoSiCaPs with 66.6 and 83.3 
NanoSiCaPs were statistically significant (p<0.05), indicated by asterisk (*). 
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3.3.4 Transmission electron microscopy analysis of NanoCaPs and NanoSiCaPs 
complexes 
TEM was used to qualitatively assess the particle size and morphology of the un-substituted 
NanoCaPs and NanoSiCaPs complexes (8.3, 50 and 83.3 mol% Si substitutions). As shown in 
Figure 3.10, un-substituted NanoCaPs and NanoSiCaPs complexes appear to be spherical in 
nature. However, for the un-substituted NanoCaPs, all the particles observed appear 
agglomerated and with the increase in substitution, the particles appear to be smaller and less 
agglomerated demonstrating the influence of Si substitution. The particle size estimate for un-
substituted NanoCaPs complexes is in the range of 80-100nm where as for the NanoSiCaP 
complexes, the particle size is in the smaller size range of 50-100nm size.  
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Figure 3.10. TEM images of NanoCaPs and NanoSiCaPs complexes. 
 (a) un-substituted NanoCaPs complexes, (b) 8.3 NanoSiCaPs complexes, (c) 50 NanoSiCaPs 
complexes and (d) 83.3 NanoSiCaPs complexes. 
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3.4 DISCUSSION  
There are many potential implications for substituting metallic or non-metallic ionic species into 
HA, since the substitutions are likely to cause complex structural changes at the unit-cell level 
[143]. Possible consequences of such ionic substitutions include changes in the physical and 
chemical properties of HA such as lattice parameter, particle morphology, crystallinity, thermal 
stability, surface chemistry, overall phase solubility, as well as kinetics of dissolution [106, 107, 
135, 144]. Silicon has been reported to be incorporated as a substituent into HA, tri-calcium 
phosphate (TCP) [145] and bone cements [146], even though HA continues to remain the most 
popular choice for generating substituted apatites. It has also been demonstrated that the 
substitution of silicon into HA increases the in vivo bioactivity of HA by enhancing its 
dissolution and that the dissolution rate is enhanced by the presence of site deficiencies and 
crystallographic imperfections within the HA structure created by the different ionic 
substitutions [137, 147, 148]. The fact however, still remains that silicon substitution into HA 
creates a vast range of improvements over pure HA in the field of bioactive bone substitutes. 
This proven conclusion indicates that it is also possible to achieve similar effects by 
incorporating silicon into the already published and demonstrated efficacy of NanoCaPs as gene 
delivery vectors. Therefore, the aim of the current study was to investigate the critical 
concentration of silicate ions that could be incorporated into the HA lattice without inducing a 
phase change and consequently, evaluate the gene delivery potential of the silicate substituted 
HA which is aptly termed as NanoSiCaPs.  
Unlike conventional methods involving hydrothermal treatments to force the 
incorporation of ionic substituents into the HA lattice at extreme temperatures, this study focused 
on a simple aqueous precipitation approach at room temperature, under ambient pressure and 
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more importantly, physiological conditions. From the XRD and FTIR data it is clear that the as-
prepared HA and SiHA are indeed semi-amorphous, and nanocrystalline in nature, but 
nevertheless, display the presence of the HA phase only at low concentrations of silicate. With 
increase in silicate substitution, the XRD patterns become completely amorphous for 33.3SiHA, 
and upon further increase in the silicate concentration in addition to the semi amorphous phase, 
there is also the presence of a secondary phase of calcium silicate hydrate having a structure of 
1.4 nm crystallite size phase of tobermorite (Figure 3.3). 
Based on the published literatures the exact amount of silicate ion incorporation is not 
well established. However, some recent literature clearly suggests that low levels of silicon, in 
the range of 0<Si wt. %< 3.51, substitution is possible into the HA lattice [135]. Although the 
synthesis conditions used in our study is very different from the work reported earlier, the 
agreement nevertheless is a validation of the solubility of low silicate concentrations into the HA 
lattice with varying starting precursors, and the formation of single-phase HA structure with no 
evidence of any crystalline secondary phase. 
In addition, FTIR data reveals that other than very slight wavenumber shifts in some of 
the band positions (Figure 3.4), the 8.3SiHA spectrum very closely matches that of the un-
substituted HA. It is also evident that as the Si substitution increased beyond 33.3 mol %, the 
intensities of the PO4 bands become less prominent, which correspond to decreasing phosphate 
and increasing silicate incorporation into the SiHA. In addition to the changes in the PO4 bands 
intensities, the OH bands at 3571 (stretching) cm-1 and 631cm-1(bending) also decreased in 
intensity for the 8.3SiHA sample and disappeared altogether for samples with 33.3 (mol%) Si 
substitution and beyond. This may be due to two possible phenomena occurring. First, increasing 
the Si substitution could lead to the OH- groups being substituted by the SiO44-, or second, loss of 
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OH- groups in order to maintain the overall charge balance [149, 150]. Moreover, the FTIR 
spectra of the as-dried samples present the characteristic pattern of partially carbonated hydrated 
hydroxyapatites, as extensively discussed elsewhere [151]. It is also clear that all of the silicates 
for low levels (≤16.6 mol % or ≤2.8 wt. %) of substitution exhibited the partially hydrated 
carbonated HA phase. The incorporation of atmospheric CO2 into the HA structure during the 
synthesis is also well known which results in the formation of carbonated substituted 
hydroxyapatite or dahllite [138]. According to literature, the presence of carbonate ion within the 
as-precipitated apatite phase is also known to inhibit the conversion of the amorphous precipitate 
to the crystalline phase [152, 153], thus being responsible for the low crystallinity of the as-
precipitated samples as evidenced by the XRD results. The influence of time-temperature history 
on the as-prepared powders were however, not included in this study as the main focus was 
primarily on the synthesis of silicate-substituted nanoparticles for in-vitro gene transfection 
under ambient conditions. 
Due to the semi amorphous nature of the as-prepared samples it was difficult to detect or 
distinguish any preferential morphology of the particles. As the particles were agglomerated, 
presence of any distinct secondary phase morphology for 50SiHA and 83.3SiHA was not 
unequivocally visible (Figure 3.5). However, EDAX spectra collected from the SEM images 
revealed the elemental composition of the samples (Figure 3.6). As anticipated, the 8.3SiHA 
sample exhibited a larger P peak than Si peak, while the 83.3SiHA sample showed the opposite, 
corresponding to the initial nominal precursor amount of P and Si.  
It should also be noted that the obtained ratio of Ca/P of 1.57 by EDAX in the as 
prepared HA is very similar to the value reported earlier by our group using ICP-OES [154]. The 
non-stoichiometry of the as prepared HA powder by simple precipitation is very common and is 
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known to mostly depend on the influence of various process parameters[154, 155] and also due 
to the formation of defects such as vacancies in the crystal lattice[156, 157], and also the 
substitution of diverse ions such as carbonate, sodium and chloride in the lattice structure[158]. 
Therefore, the slight decrease in (Ca/P+Si) ratio for 8.3SiHA (Figure 3.6) is not surprising and 
most likely due the formation of vacancies or defects and other ion substitutions into the HA 
structure. However, a large decrease in (Ca/P+Si) ratio for the 50SiHA and 83.3SiHA is most 
likely due the presence of a secondary phase in addition to the vacancies or substitution of by 
other ions in the HA structure. The XRD and FTIR results (Figure 3.2, Figure 3.3 and Figure 3.4) 
have confirmed the formation secondary phases of 1.4-nm crystallite sized tobermorite phase 
(Ca5Si6O16(OH)2). 8H2O) and other amorphous calcium silicate hydrate phase. The Ca/Si ratio in 
tobermorite is 0.83 and therefore, it expected that the formation of tobermorite will reduce the 
overall (Ca/P+Si) ratio. This also implies that some part of the calcium salt remained unreacted 
in the solution and did not precipitate due to the lack of critical concentration of anions necessary 
for reaching the required solubility product to initiate the precipitation of the compound. 
The in vitro gene delivery potential of NanoCaPs and NanoSiCaPs was evaluated using 
pDNA encoding GFP on a hard to transfect [159], NIH-3T3 fibroblast cell line and MDA-MB-
231, a breast cancer cell line (Figure 3.8). At higher levels of silicate substitution, the chemical 
composition of the nanoparticles appeared to have a major impact on the gene delivery results. 
As evidenced from the XRD and FTIR results, formation of different phases at high levels of 
silicate substitution and their varying ability to bind pDNA together could be attributed for the 
decline in the observed gene delivery transfection results for these samples. The drastic decline 
in DNA loading efficiency in these samples therefore resulted in the poor transfection levels 
since the majority of the initial DNA was unable to be bound to the NanoSiCaPs gene delivery 
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carriers (Figure 3.9) due to the likely presence of multiple phases with poor pDNA binding 
affinity as discussed above.  Further, the differences in the negative charge caused by the 
incorporation of higher amounts of silicate could have led to increased repulsion between the 
silicate and the negatively-charged DNA, as well as the increase in the site defects and vacancies 
within the structure of NanoSiCaPs caused by higher silicate substitution. All of these aspects 
could contribute to the decreased capacity for the NanoSiCaPs of higher silicate content to 
efficiently bind DNA. Due to these reasons, increasing the silicate substitutions to a large degree 
primarily contributed to causing a reduction in the observed transfection efficiency. Additionally, 
we assessed transfection efficiency of NanoSiCaPs (8.3 mol% Si) with commercially available 
transfection reagents (see Section A.3 for results and discussion).  
On the other hand, 8.3 NanoSiCaPs that maintained the HA structure indicated a two-fold 
increase in the transfection efficiency for NIH-3T3 cells (Figure 3.8). Previous studies have 
indicated that incorporation of silicate ions into the HA lattice would distort and destabilize the 
structure, therefore making it energetically favorable for substituted HA to dissolve faster than 
the as prepared HA phase [136]. This higher solubility and unstable characteristic of Si 
substituted HA could play a crucial role in the rapid dissolution of the endocytosed nanoparticles 
and thus facilitate escape of the lysosomal degradation, preserving the DNA in its pathway to the 
nucleus. The faster dissolution will lead to rapid release of ions in the endosomes and these ions 
will in turn increase the osmotic pressure thereby rupturing the endosome membrane enabling 
release of their contents in the cytosol.  
In order to validate this reasoning, dissolution characteristics for other anion and cation 
substituted calcium phosphate gene delivery systems have been investigated [104, 106, 107]. 
Dissolution of the as prepared HA and SiHA samples in Bis-Tris buffer (Figure 3.7) clearly 
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showed that the silicate substituted samples underwent more dissolution as compared to HA. ICP 
data also clearly indicated that higher amounts of calcium ions are released from the SiHA 
samples in the buffer system having a physiological pH-7.2, early endosome pH-6.5 and late 
endosome pH-5.8 (Figure 3.7). ICP analysis of 50SiHA and 83.3SiHA at pH-7.2 also shows that 
at higher concentrations of silicate, the prepared SiHA samples are unstable at physiological pH 
and undergo rapid dissolution, thereby further explaining the low transfection and pDNA binding 
capabilities of these samples. This result also clearly indicates that Si gets incorporated into the 
HA lattice at low levels of substitution, which thereby influences the dissolution characteristics 
of the as prepared samples. The presence of Si in the as prepared samples is also extensively 
explained by Hayakawa et al, wherein the authors have shown that as prepared SiHA consists 
mainly of partially amorphous hydrated and carbonated calcium phosphate incorporating 
polymeric silicate specie [136]. It is indeed the presence of Si in the system that leads to 
accelerated degradation of apatite particles in line with our observations reported here. TEM 
analysis of the complexes also revealed that the particles tend to agglomerate less with silicate 
substitution (Figure 3.10). However, the primary particle size of NanoCaPs-pDNA and 
NanoSiCaPs-pDNA seem to be in the same range of 50-100nm, although the NanoSiCaPs 
complexes consist of smaller aggregates. This trend was also observed at multiple locations on 
the TEM grid for NanoCaPs and 8.3 NanoSiCaPs. On the other hand, 50 and 83.3 NanoSiCaPs-
pDNA complexes had nearly no aggregate formation to an extent that it was difficult to image 
any complexes for 83.3 NanoSiCaPs-pDNA. This can also be attributed to the poor stability of 
these samples under physiological pH as evidenced in the dissolution study (Figure 3.7), which 
can explain the presence of fewer particles for these samples in the TEM analysis. These results 
are in accordance with previous reports describing cationic substitution of magnesium and 
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anionic substitution of fluoride ions, wherein substitution of ions in trace amounts resulted in 
enhanced transfection owing to faster dissolution and reduced particle aggregation of CaP based 
vectors [104, 105]. Therefore, combination of rapid dissolution and smaller agglomerate 
formation of the NanoSiCaPs-pDNA complexes combined with the maintenance of the HA 
structure result in efficient pDNA binding and condensation. In summary, these aspects 
altogether thus render 8.3 mol% Si substituted NanoSiCaPs a superior gene delivery vector 
compared to pure and unsubstituted NanoCaPs.  
3.5 CONCLUSIONS 
In this study different silicate substituted nano-particulates of calcium phosphates were prepared 
and characterized using XRD, FTIR, SEM and TEM. Silicate substitution below a certain 
concentration (x ≤ 16.6 mol %) retains the single phase of partially hydrated and carbonated 
hydroxyapatite structure. Upon increasing the silicate incorporation (16.6 mol % ≤ x ≤ 33.3 mol 
%), the nanoparticles of hydroxyapatite phase of calcium phosphate changes to an amorphous 
form and upon further increase in substitution (x ≥ 33.3 mol %) leads to formation of 
nanoparticles containing hydrated calcium silicate phases. pDNA transfection results indicate 
that 20-50 % increase in transfection was observed for 8.3-50 mol % silicate containing samples 
compared to NanoCaPs. However, further silicate substitution (>60 mol %) resulted in 
considerable reduction in transfections. Instability of the silicate substituted NanoCaPs and the 
optimal concentration of Si responsible for maximal binding of pDNA result in the 8.3 mol% Si 
substituted NanoSiCaPs demonstrating optimal transfection. From these results it can thus be 
concluded that suitable concentration of substitution of phosphates by silicates in nanostructured 
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calcium phosphates forming NanoSiCaPs thus significantly improve the in-vitro pDNA 
transfection suggesting NanoSiCaPs to be promising gene delivery systems. 
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4.0  FABRICATION OF POLYELECTROLYTE NANOSICAPS ASSEMBELIES ON 
TITANIUM SUBSTRATES FOR SURFACE MEDIATED GENE DELIVERY 
4.1 INTRODUCTION 
Surface properties of biomaterials play a crucial role in determining the initial host tissue 
response, which in turn plays a significant role in determining the long-term success of the 
implants [161, 162]. Surface mediated gene delivery from implants is an attractive approach to 
stimulate specific cellular response at the molecular level [163]. Currently, layer by layer (LbL) 
assembly [164] and biomineralization [39] are two common approaches for surface modification 
of orthopedic implants to incorporate substantial amounts of plasmid DNA (pDNA) on the 
implants. However, these methods involve prolonged incubation ( >48 hours) of substrates in 
supersaturated calcium phosphate solution [165, 166], or multistep procedures comprising 
alternate dipping cycles in polycationic and polyanionic solutions [167]. Therefore, herein we 
focused on the development of a novel surface modification technique that: 1) involves a quick 
and easily adaptable methodology applicable to materials used for dental and bone repair, with 
different geometries and composition; 2) provides an easily accessible medium promoting cell 
attachment and proliferation; and 3) acts as a gene-activating material [163].  
Commercially available pure Ti is by far one of the most widely used material for dental 
and bone repair due to its superior mechanical properties and biocompatibility [168, 169]. 
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However, despite its beneficial properties numerous physical and chemical methods are 
employed for surface modification of Ti surfaces to promote osseointegration [168, 170]. 
Therefore, gene delivery through the Ti surface makes it an ideal choice of substrate for the 
current study. Chapter 3 described the development of NanoSiCaPs, a modified version of our 
previously reported work on nanostructured calcium phosphate particles (NanoCaPs), with 8.3 
mol% or 1.4 weight% of silicate substituted in lieu of the phosphate [160]. This substitution 
resulted in two-fold increase in gene transfection capability of NanoSiCaPs, due to its superior 
solubility and ensuing materials properties [160]. As outlined in Figure 4.1, our goal is to 
incorporate NanoSiCaPs (complexed with pDNA) on Ti substrates, where NanoSiCaPs mediate 
the delivery of plasmid DNA (pDNA) to MC3T3-E1, a murine pre-osteoblasts cell line, seeded 
on top of the Ti surface.  
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Figure 4.1. Schematic representation of fabrication of Ti-polyelectrolyte NanoSiCaPs assembly 
(PNA). 
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4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Calcium chloride (CaCl2⋅2H2O, 99% purity), trisodium phosphate (Na3PO4⋅12H2O), sodium 
chloride (NaCl), dextrose, AlamarBlue Cell Viability Assay were purchased from Fisher 
Scientific (Pittsburgh, PA). Poly-(diallyl-dimethyl-ammonium chloride) medium molecular 
weight (Mw 100-200kDa, 20wt% in water), Potassium chloride (KCl, 99+%), 
Paraformaldehyde, and Phalloidin-Tetramethylrhodamine B isothiocyanate (phalloidin-TRITC) 
was purchased from Sigma Aldrich (St. Louis, MO). 4',6-Diamidino-2-phenylindole (DAPI) was 
purchased from PacReacAppliChem (Maryland Heights, MO). Sodium hydroxide (NaOH) was 
purchased from Mallinckrodt Baker Inc. (Phillipsburg, NJ). Sodium metasilicate 
(Na2SiO3⋅5H2O) and Titanium (Ti) (99.7%, metal basis), 0.89mm thick, was purchased from 
Alfa Aesar (Ward Hill, MA). HEPES (99%) and were obtained from EMD Chemicals 
(Gibbstown, NJ). Reporter plasmid, gWizTM GFP (Green Fluorescent Protein) was purchased 
from Aldevron LLC (Fargo, ND). All the reagents were used as received without further 
modification or purification.  
4.2.2 Synthesis and fabrication of Ti-PNA 
4.2.2.1 Substrate preparation 
Titanium substrates were cut into squares of 1 cm x 1 cm x 0.89mm and cleaned using acid 
etching and repeated washing with acetone. The substrates were then polished with 320, 600 and 
1200 grit SiC paper and cleaned under ultrasonication using acetone. 
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4.2.2.2 Fabrication of Ti-PDADMAC 
Cleaned Ti-substrates were immersed in PDADMAC solution (5 mg/mL), in phosphate buffer 
(pH-7.5) at room temperature (RT). After 15 minutes the substrates were then drawn at a 
constant speed of 200 µm s-1 using a dip coater (Desktop Dip Coater, MTI Corporation, USA, 
Model No EQ-HWTL-01-A). Substrates were subsequently washed in deionized (DI) water for 1 
minute and dried at RT. 
4.2.2.3 Synthesis of NanoSiCaPs complexes 
NanoSiCaPs were synthesized according to a protocol previously described (see Section 3.2.3). 
Briefly, 62 μl of 2M CaCl2 and 25.6 μl of plasmid DNA (1mg/ml, gWiz GFP) were diluted in 
412.4 μl of ddH2O to form solution A (500μl total). An equal volume (500μl) of solution B 
containing HEPES-buffered solution (280 mM NaCl, 10 mM KCl, 12 mM dextrose, and 50 
mMHEPES) with 1.37 mM of Na3PO4 and 0.13 mM of Na2SiO3 [160]. The HEPES-buffered 
solution was intended to maintain the pH of the precursors at 7.5. The molar ratios of Ca/(P+Si) 
maintained at 130. NanoSiCaPs were then synthesized using a Harvard Apparatus PHD 2000 
Infuse/Withdraw syringe pump (Holliston, MA) to introduce and mix the two solutions in a 
controlled drop wise fashion to generate a homogeneous dispersion of the NanoSiCaPs in 
solution. Hence, solution A was added drop by drop into solution B at an addition rate of 
13.4μl/s while solution B was vortexed at 500 rpm (Figure 3.1). The addition rate and molar ratio 
of  Ca/(P+Si) was also selected following our previously published report [171]. 
4.2.2.4 Fabrication of polyelectrolyte NanoSiCaPs assemblies (PNA)  
Ti-PDADMAC substrates were gently placed in a 24-well plate. 1 mL of freshly synthesized 
NanoSiCaPs was added for each substrate and incubated for 10 minutes at room temperature 
 63 
(RT) in the cell culture hood. After 10 minutes of incubation, substrates were carefully 
withdrawn manually with help of tweezers and allowed to dry at RT for 5 minutes. Substrates 
were subsequently washed by dipping in DI water for 1 minute. Coated substrates were then 
either used for cell culture studies or stored in desiccator for surface characterization studies 
(Figure 4.1). For some studies, where specified, Ti-PDADMAC-pDNA substrates were also 
made, by immersing Ti-PDADMAC substrates in equal volume of pDNA solution (25.6 µg in 
1ml DI water). 
4.2.3 Surface characterization techniques 
PDADMAC polymer solution, bare Ti and Ti-PDADMAC were analyzed using attenuated total 
reflectance Fourier transform infrared spectroscopy (FTIR; Nicolet 6700 Thermo Scientific). The 
spectra were collected in the range of 4000–500 cm−1. The surface morphology of Ti-PNA was 
studied using scanning electron microscopy (SEM) with a Philips-XL30 FEG operating at 
10.0 kV. All the samples used for SEM analysis were coated with Pd using a sputter coater 
system. The surface topography and roughness of the bare Ti, Ti-PDADMAC and Ti-PNA were 
characterized by non-contact atomic force microscopy (AFM) using MFP-3D AFM (Asylum 
Research) and Igor Pro (Wavemetrics) analysis software as previously described [172]. 
Topography images of 80 by 80 microns were taken with a silicon nitride conical tip (k = 40Nm-
1, Mikromasch, Ltd) at a scan rate of 1Hz and 512 by 512-pixel resolution.  Root mean square 
(RMS) surface roughness quantification was performed at n = 3 random 20 by 20-micron regions 
within the images. Water contact angle was determined using a Theta Lite Optical Tensiometer 
(Attension, Biolin Scientific) equipped with image analysis software (Theta Lite). By applying 
the sessile drop method, drop of 200 pixels were created at the tip of the syringe and carefully 
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placed on top surface of the substrate. Measurements were conducted immediately after placing 
the drop at RT. The contact angle was calculated using the Young-Laplace fit equation.  
4.2.4 In-vitro experiments 
Murine osteoblast cell line MC3T3-E1 was obtained from ATCC (Manassas, VA). Cells were 
cultured in humidified incubator at 37 °C and 5% CO2, in minimum essential medium alpha 
(MEM α; Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) and 1 % 
penicillin/streptomycin (P/S). Cells at third to seventh passage were used in these 
experiments. For in-vitro transfection, cells were plated at a density of 4.0 x 104 cells on tissue 
culture polystyrene (TCPS) as control, Ti-PDADMAC-pDNA and Ti-PNA substrates placed in a 
24-well plate. Level of GFP-expression was qualitatively assessed using fluorescence 
microscope (Olympus, CKX41). For quantitative analysis of GFP expression, flow cytometry 
was performed on day 3. Growth media was aspirated out from each well and phosphate buffered 
saline (PBS, pH-7.4) was added (500 µl each) to wash off the FBS, which can inhibit trypsin 
action. After about 30 s, the PBS was aspirated and 200 μl of 0.5% trypsin-EDTA solution was 
added to each well. The cells were incubated in trypsin for ~3 minutes at 37 °C followed by 
addition of 800 μl of growth media containing FBS. After some agitation to ensure removal of 
all the cells from the well surface, the suspension was aspirated into epi-tubes and centrifuged at 
500 rpm for 5 minutes. The supernatant was aspirated; the cells were re-suspended in 400 μl PBS 
(pH-7.4) and transferred to 15 mm tubes for flow cytometry. On the Accuri C6 (Accuri 
Cytometers, Ann Arbor, MI) flow cytometer, the FL1-A filter set corresponds to the GFP 
wavelengths. The cells were selected using a forward v/s side scatter plot from a sample of GFP 
negative cells as control (cells plated on TCPS). This also gave us a filter for auto fluorescence. 
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After negating the auto fluorescence, the ratio of GFP-positive to total number of cells was 
obtained for each well (total of 5000 cells were counted for each sample, n=3). This ratio was 
used as a measure for calculating the % transfection efficiency. In vitro viability of MC3T3-E1 
cells at different time points (n=3) was performed using AlamarBlue Cell Viability Assay 
according to manufacturer’s protocol. Media containing 1/10 volume of Alamarblue was freshly 
prepared and incubated at 37°C for 3 hours to measure cell activity. Media was transferred to 96-
well plates and then measured the fluorescence at 560nm/585nm (excitation/emission) using 
microplate reader (Biotek, Synerge2). Qualitative assessment of pDNA coverage on coated 
substrates was performed using DAPI staining. DAPI staining solution was diluted in PBS at 
300nM and then added to bare Ti, Ti-PDADMAC-pDNA and Ti-PNA substrates. Substrates 
were incubated for 15 minutes, washed in PBS then imaged using fluorescence microscope 
(Olympus, CKX41). Cytoskeletal staining of filamentous actin (F-actin) was visualized using 
Phalloidin-Tetramethylrhodamine B isothiocyanate (phalloidin-TRITC).  Cells attached to 
substrates (bare Ti, Ti-PDADMAC and Ti-PNA) were fixed using 4% Paraformaldehyde for 10 
minutes then incubated 0.1% tritonX 100 to facilitate permeabilization. After blocking in 1% 
BSA, cells were incubated with phalloidin-TRITC for 40 minutes at room temperature washed 
with PBST then imaged with fluorescence microscope (Olympus, CKX41). DAPI was used as a 
counter stain.  
4.2.5 Statistical analysis  
Statistical calculations were performed using GraphPad Prism software. The data was analyzed 
to test for mean differences on contact angle, RMS values, in vitro cell viability results for 
different samples using one-way analyses of variance (ANOVA) and p-value of <0.05 was 
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considered statistically significant. Each ANOVA on these response variables was significant at 
p<0.05, n=3. Post hoc tests for pair-wise differences and identification of homogeneous 
subgroups were performed using the Tukey HSD procedures for contact angle and RMS 
measurements. For in-vitro transfection analysis using flow cytometry, paired t-test was 
performed with a p<0.05.  
4.3 RESULTS 
4.3.1 Surface characterization  
FT-IR was used to confirm the presence of PDADMAC on Ti substrates. The FT-IR spectrum of 
Ti substrate coated with PDADMAC matched the spectrum of pure PDADMAC with IR 
absorption peaks at 1470cm-1 (C-H2 stretching) and 1409cm-1 (symmetric bending mode of the 
+N-CH3 group) [173, 174] indicating the presence of PDADMAC on the Ti substrates (Figure 
4.2).  
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Figure 4.2. FTIR spectrum of coated substrates. 
 
 
The surface morphology of the coated substrates was investigated using scanning electron 
microscopy (SEM) and atomic force microscoy (AFM). SEM images of the Ti-PNA are shown 
in Figure 4.3, which suggests that NanoSiCaPs were uniformly coated on the entire Ti substrate 
(Figure 4.3a). Moreover, the primary particle size of the NanoSiCaPs are in the range of 50-
100nm as reported in our earlier work [160] (Figure 4.3).  
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Figure 4.3. SEM micrograph of Ti-PNA.   
(a) scale 20µm and (b) scale 1µm. 
 
 
AFM images of Ti-PNA films are generated using non-contact mode shown in Figure 4.4a, 
Figure 4.4c and Figure 4.4e. Root mean square (RMS) surface roughness quantification was 
performed at (n = 3) random 20 by 20-micron regions within the images. The surface 
morphology of the coated substrates changes from a smooth surface for bare Ti, RMS~80nm and 
Ti-PDADMAC films, RMS~45nm (Figure 4.5), to a rougher surface covered by the complexed 
particles after NanoSiCaPs adsorption, RMS~145nm. To further illustrate these differences, 3D-
image reconstructions for the Ti-PNA films is presented in Figure 4.4b, Figure 4.4d and Figure 
4.4f. SEM and AFM analysis proved the change in surface morphology upon fabrication of PNA 
on Ti-surfaces.  
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Figure 4.4. AFM analysis of coated substrates.  
AFM height images of (a) bare Ti, (c) Ti-PDADMAC and (e) Ti-PNA (scale 20µm). 3-D image 
reconstruction of AFM height images showing the morphology of: (b) bare Ti, (d) Ti-PDADMAC and (f) Ti-
PNA. 
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Figure 4.5. Surface roughness quantification of coated substrates. 
Root mean square (RMS) roughness quantification using AFM (p<0.05). The data were reported ± 
SD, n=3. 
 
 
Additionally, surface wetting properties was also investigated by measuring the water contact 
angle at three separate locations on the coated substrates. It was determined that the contact angle 
of bare Ti (61.5±2.1°) was similar to Ti-PDADMAC (63±3.5°), as shown in Figure 4.6. 
However, the contact angle decreased to 29±1.4° (p<0.05), with accompanying NanoSiCaPs 
adsorption on the substrates, which suggests that the adsorption of NanoSiCaps renders the 
surface more hydrophilic.   
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Figure 4.6. Contact angle measurements. 
Water contact angle measurements on bare Ti, Ti-PDADMAC and Ti-PNA (P < 0.05). The data were 
reported ± SD, n=3. 
 
 
Presence of pDNA on the Ti-PNA films was detected by DAPI staining of the substrates (Figure 
4.7). Overall, surface characterization results demonstrate that PNA coating strategy is successful 
in obtaining a nanoceramic coating on Ti substrates and has a direct influence on the surface 
properties of the substrates.  
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Figure 4.7. DAPI staining of coated substrates. 
DAPI staining of substrates showing presence of pDNA in the coatings. (a) bare Ti, (b) Ti-
PDADMAC-pDNA and (c) Ti-PNA (scale 200µm).  
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4.3.2 In-vitro transfection  
In-vitro transfection potential of Ti-PNA was evaluated using pre-osteoblast (MC3T3-E1) cells. 
Subject to the same conditions, a control group received equal amounts of pDNA on Ti-
PDADMAC substrates, but without NanoSiCaPs. Substrates were prepared on the day of cell 
seeding. GFP expression of the transfected cells was monitored using a fluorescent microscope. 
Transfected cells were observed as early as day 1 and the GFP expression peaked at day 3 
(Figure 4.8) for Ti-PNA, while the substrates lacking NanoSiCaPs (only pDNA) showed little to 
no GFP expression, Figure 4.8d, Figure 4.8e and Figure 4.8f. GFP expression of MC3T3-E1 
cells was also quantified using flow cytometry at day 3, Figure 4.8g. The Ti-PNA coated 
substrates exhibited transfection in ~13% of cells, whereas the substrates lacking NanoSiCaPs 
showed no transfection in agreement with fluorescence microscopy results (p<0.05). These 
results thus indicate that Ti-PNA serves as a gene-activating material and highlights the 
importance of incorporating a pDNA vector in the coating to achieve successful delivery of 
pDNA to cells. 
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Figure 4.8. Surface mediated in-vitro transfection of MC3T3-E1 cells. 
Fluorescence microscopy images of MC3T3-E1 cells on: Ti-PNA on (a) day 1, (b) day 3 and (c) day 7 
(scale 200µm); Ti-PDADMAC-pDNA on (d) day 1, (e) day 3 and (f) day 7 (scale 200µm). Flow cytometry 
analysis measuring GFP expression in MC3T3-E1 cells at day 3. The data were reported ± SD, n=3 (p<0.05). 
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4.3.3 Cell attachment and viability  
Finally, we determined the cell viability of MC3T3-E1 cells seeded on the coated substrates 
using alamar blue assay™. Tissue culture polystyrene (TCPS) and bare Ti were used as control 
groups. Cell viability of the coated substrates was no different than the positive control (bare Ti) 
or the negative control (TCPS) with no statistically significant difference at each time point 
(Figure 4.9).  
 
 
 
 
Figure 4.9. Cell viability assay of coated substrates. 
 Cell viability measured using MTT assay at different time points (p<0.05). No statistical significance 
between groups (p>0.05). The data were reported ± SD, n=3.  
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The cell morphology was also observed to evaluate cell attachment and spreading on the 
substrates as cytoplasmic extensions are crucial for cell adhesion, migration and formation of 
cell-cell junctions [83, 175], which are also key factors dictating tissue integration of the 
implants [119]. MC3T3-E1 cells attached on the substrates were stained for F-actin (filamentous-
actin), a cytoskeletal element (in red) and nucleus (in blue), on day 3. Figure 4.10a-f 
demonstrates that bare Ti, Ti-PDADMAC, and Ti-PNA favorably supported attachment and 
proliferation of the pre-osteoblast cells. These results thus indicate that Ti-PNA enables 
attachment, spreading and proliferation of pre-osteoblast cells.  
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Figure 4.10. Cytoskeletal staining of MC3T3-E1 cells. 
Cytoskeletal staining showing F-actin (red) and nucleus (blue) for (a) bare Ti, (c) Ti-PDADMAC and 
(d) Ti-PNA (scale 50µm). (b) bare Ti, (d) Ti-PDADMAC and (e) Ti-PNA (scale 20µm). 
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4.4 DISCUSSION 
 Gene delivery from the surfaces of implants is a unique strategy to facilitate tissue regeneration 
and integration. However, it has been challenging, because of the difficulty to incorporate and 
deliver sufficient amounts of plasmid DNA (pDNA) to cells from the implant surface allowing 
efficient gene expression. This study shows enhanced and optimized non-viral transfection of 
MC3T3-E1 cells, murine pre-osteoblasts cells mediated via NanoSiCaPs complexes. 
Additionally, we describe a novel and simple coating approach using NanoSiCaPs that 
preferentially adsorb onto titanium (Ti) substrates coated with poly (diallyldimethylammonium 
chloride) (PDADMAC) (Figure 4.1). The Ti-polyelectrolyte NanoSiCaPs assemblies aptly called 
PNA deliver pDNA to MC3T3-E1 cells and induce protein production, without eliciting 
cytotoxicity, while simultaneously encouraging cell attachment on the substrate.  
 There were four reasons that suggested that the PNA assembly was fabricated onto the Ti 
surface. First, the presence of polyelectrolyte PDADMAC was confirmed by FTIR which 
particularly is a useful analytical technique for identification of molecular groups present, 
validating the formation of the coating (Figure 4.2). Second, the particle diameters observed via 
scanning electron microscopy (SEM) images (Figure 4.3a and Figure 4.3b) were consistent with 
the size of NanoSiCaPs complexes displayed in the TEM as reported in Section 3.2.7. The results 
also demonstrated that NanoSiCaPs complexes covered the Ti-PDADMAC coating with primary 
particle size of 100nm (Figure 4.3b). Third, AFM measurements displayed change in surface 
morphology of the Ti surface from rough to smooth surface upon PDADMAC adsorption, and to 
even rougher surface following NanoSiCaPs adsorption (Figure 4.4a-f and Figure 4.5). Fourth, 
the alternate fluctuation of contact angles of the surface indicated that the layer of PDADMAC 
and NanoSiCaPs was assembled on to the surface (Figure 4.6).  
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The polyelectrolyte used in the current study, PDADMAC, is a typical representative of a water-
soluble polycation with quaternary amines with a surface charge ~ 70mV [176]. PDADMAC is 
known for its role in separation of biomolecules [177], protein immobilization [178], and 
flocculation of silica and latex particles [179]. Zhao et al demonstrated use of PDADMAC and 
poly (acrylate sodium) (PAS, as polyanion) for synthesis of hybrid CaP particles for delivery of 
anticancer drug, which demonstrated good dispersibility and colloidal stability in water [174]. 
Due to its high surface charge, it was hypothesized that the use of positively charged, 
PDADMAC as a surface coating would enable higher adsorption of negatively charged 
NanoSiCaPs complexes [67] (zeta potential ~ -20mV) through electrostatic interactions. 
Although, the amount of NanoSiCaPs complexes adsorbed on the Ti-surface was not calculated 
in the current study, qualitative assessment of the Ti surfaces using SEM, AFM and DAPI 
staining clearly showed that the NanoSiCaPs complexes was indeed present on the Ti-
PDADMAC coatings. The practical significance of this fabrication technique is that it takes less 
than 30 minutes for adsorption of both the layers, in contrast to existing surface mediated gene 
delivery techniques using CaP based methodologies that require more than 48 hours of 
incubation in super saturated calcium phosphate solutions [122-124]. Thus, the approach 
described herein may be particularly translated to medical device applications where degradable 
scaffolds are utilized, such as Mg-based alloys, thereby avoiding any potential degradation of the 
bulk material with prolonged incubation in aqueous conditions. In addition, this methodology 
can be utilized for creation of off-the-shelf coated implants for their use in bone tissue 
engineering applications.  
 The cytocompatibility and transfection ability of the fabricated coating was assessed 
using in-vitro experiments with MC3T3-E1 cells. F-actin and DAPI staining of cells revealed 
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that the cell morphology was not affected by the presence of either the polymer or NanoSiCaPs 
coating (Figure 4.10a-f). Cell viability assay of MC3T3-E1 cells on different coatings indicated 
that the coatings with or without NanoSiCaPs complexes did not induce any significant 
cytotoxicity compared with tissue culture plastic or bare Ti (Figure 4.9). The in-vitro transfection 
results of Ti-PNA showed that GFP expression peaked at day 3 and then decreased by day 7 
(Figure 4.8a-c and Figure 4.8g), which was probably due to degradation of pDNA and cell 
proliferation. On the other hand, Ti-PDADMAC-pDNA samples showed very little transfection 
at all-time points (Figure 4.8d-f and Figure 4.8g). These results indicated the importance of 
including a transfection agent in achieving successful surface mediated gene delivery. Other 
commercially available cationic polymer-based transfection vector was not incorporated in the 
current study for comparison since the fabrication technique relied on electrostatic interaction 
between the positively charged polymer, PDADMAC and negatively charged complexes, either 
pDNA alone or NanoSiCaPs (with pDNA).  
Although, direct comparison of transfection results observed in this study with surface 
mediated results reported by others is not possible at large, some generalizations can be made 
based on studies incorporating same cell-line and reporter gene (GFP) for estimating transfection 
efficiency.  Notably, Liu et al reported assembly of multilayers of cationic lipid/pDNA (LDc) 
and hyaluronic acid (HA) on Ti surfaces by LBL technique [180]. The authors estimated 
transfection efficiency of MC3T3-E1 cells by measuring the GFP expression of transfected cells. 
The authors observed highest transfection efficiency at day 1 with 21.25% GFP positive cells, 
which decreased to 7.37% GFP positive cells by day 3 [180]. In contrast, the Ti-PNA displayed 
13% GFP positive cells by day 3. It is also important to note that the high transfection efficiency 
reported by the Liu et al on day 1 was for the Ti-samples coated with 8 bi-layers of HA/LDc 
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[180], whereas the current study only incorporated one layer of NanoSiCaPs on the Ti surface. 
Decline in transfection efficiency by day 3 for the reported work was attributed to the fact of 
potential cytotoxicity of cationic lipids incorporated in the bi-layers [180], which was consistent 
with a previous study [181]. This further proves the cytocompatibility and efficiency of 
NanoSiCaPs vectors in comparison to reported lipid and cationic polymer based non-viral vector 
systems. In light of this knowledge, the polyelectrolyte NanoSiCaPs assembly (PNA) studied 
here may offer great opportunities for achieving enhanced surface mediated non-viral gene 
delivery for localized gene delivery applications for functional bone tissue repair and 
regeneration.  
4.5  CONCLUSIONS 
We have developed a novel two-step, and a user-friendly coating strategy on Ti surfaces using 
electrostatic interaction between a polycation, PDADMAC and negatively charged NanoSiCaPs. 
Interestingly, the coated Ti-PNA substrates enable rapid cell attachment, spreading and 
proliferation of the pre-osteoblast cells. Most notably, the entire PNA fabrication process 
requires only 30 minutes to obtain a nanoceramic complexed coating, and this methodology can 
be easily used to coat various substrates of different composition and geometries due to its 
simplicity. The in-vitro transfection results indicate that Ti-PNA is an excellent platform for 
surface mediated gene delivery, offering the potential to generate and herald a new class of 
surface functionalized gene-stimulating biomaterials for clinical application. Future studies will 
involve testing these biomaterials in animal experiments to further validate the bioactivity of the 
coated PNA architectures.  
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5.0  FORMULATION AND SYNTHESIS OF 3-D GENE DELIVERY SYSTEM USING 
FIBRIN HYDROGELS TO ENCAPSULATE NANOSICAPS 
5.1 INTRODUCTION 
Incorporation of therapeutic genes into 3-D biomaterials is a promising strategy for enhancing 
tissue regeneration. Even though it was demonstrated in the previous chapter that NanoSiCaPs 
complexes can be immobilized on top of Ti substrates to achieve surface mediated gene delivery, 
there is still, a need for 3-D gene delivery system (GDS that can provide sustained release of 
NanoSiCaPs from the bulk of the scaffold. Additionally, precise control over the amount of 
NanoSiCaPs incorporated in the scaffold would be beneficial, which was lacking in the surface 
modification technique. Therefore, work described in this chapter focuses on the development of 
3-D scaffolds than can provide precise control over the amount of NanoSiCaPs incorporated in 
the scaffold for achieving sustained gene expression.  
Nucleic acids have been incorporated into and delivered from a variety of materials 
including natural, synthetic, ceramic as well as composite materials [183]. Among these 
materials, naturally derived polymers are favorable because they are biocompatible, 
biodegradable and further, they possess a natural affinity for growth factors [15]. As a result, 
they are attractive candidates for tissue engineering purposes including protein-based polymers, 
such as collagen, gelatin, alginate, fibrin, etc, as well as polysaccharide-based polymers such as 
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chitosan, alginate and hyaluron [15]. For the current application fibrin has been selected as the 
carrier matrix for the nanoparticles because of the following reasons: 1) Fibrin is the only agent 
approved as a hemostat, sealant, and tissue adhesive by the Food and Drug Administration 
(FDA); 2) Fibrin plays a leading role in hemostasis and wound healing; 3) Its ability to support 
cell adhesion, spreading, proliferation, and angiogenesis; 4) Ease of manipulation of material 
properties of resulting fibrin hydrogels [184-186]. Although, fibrin hydrogels have been 
employed for bone tissue engineering applications for delivery of growth factors [187, 188], cells 
[189, 190],  mRNA [191], and plasmid DNA delivery via viral particles [192, 193] or lipoplexes 
[194-196], there are no reports to date however, on use of fibrin gels encapsulating CaP based 
vectors for pDNA delivery. Therefore, in this aim we explore the use of fibrin hydrogels to 
incorporate NanoSiCaPs complexes for scaffold mediated gene delivery.  
In addition to developing a 3-D scaffold for NanoSiCaPs delivery, it is also crucial to 
develop a technique that allows long-term storage of NanoSiCaPs complexes under ambient 
conditions. This would allow the transport of pre-made NanoSiCaPs complexes and eliminate 
the need for freshly preparing the complexes prior to synthesis of Fibrin-NanoSiCaPs hydrogels, 
thereby making them feasible to use under a clinical setting. For this purpose, we assessed the 
ability of sucrose to preserve both the nanoparticle size as well as the transfection efficiency of 
the NanoSiCaPs complexes. The use of disaccharides as an effective lyoprotectant is well 
established [115, 116, 197-199]. It is believed that disaccharides stabilize the nanoparticles 
during the free-drying steps via the “water replacement” and the “vitrification” processes [111]. 
However, the main objective of the current study was to evaluate the effect of sucrose as a 
stabilizing agent for lyophilization of NanoSiCaPs complexes and maintain their transfection 
efficiency.  
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The long-term objective of this work is to develop a gel form of the Fibrin-NanoSiCaPs scaffold 
that can be used either alone or to infiltrate scaffolds commonly employed in bone tissue 
engineering. Therefore, this aim focuses on the development of a gene delivery system using 
fibrin as the degradable matrix incorporating freshly prepared and lyophilized NanoSiCaPs 
complexes over a 3-D volume, which promotes cell attachment, infiltration, proliferation and 
subsequent gene transfection. The present study is the first step towards this goal and describes a 
method to incorporate lyophilized NanoSiCaPs complexes in fibrin gel under physiological 
conditions (Figure 5.1). The present study characterizes the gel micro structure, in-vitro 
cytocompatibility, transfection efficiency of lyophilized NanoSiCaPs and Fibrin-NanoSiCaPs 
formulations.   
 
 
 
 
Figure 5.1. Schematic representation of Fibrin-NanoSiCaPs gel formulation.  
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5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Calcium chloride (CaCl2⋅2H2O), tri-sodium phosphate do-decahydrate (Na3PO4⋅12H2O), sodium 
chloride (NaCl), Bis-Tris, and dextrose were purchased from Fisher Scientific (Pittsburgh, PA). 
Potassium chloride (KCl) was purchased from Sigma Aldrich (St. Louis, MO). Sodium 
hydroxide (NaOH) was purchased from Mallinckrodt Baker Inc. (Phillipsburg, NJ). Sodium 
metasilicate (Na2SiO3⋅5H2O) was purchased from Alfa Aesar (Ward Hill, MA). HEPES obtained 
from EMD Chemicals (Gibbstown, NJ). Reporter plasmid, gWiz GFP (Green Fluorescent 
Protein), were purchased from Aldevron LLC (Fargo, ND) , Reporter gene expression plasmid 
with secreted embryonic alkaline phosphatase (SEAP) pSELECT-zeo-SEAP plasmid, 
Recombinant SEAP protein and QUANTI-Blue detection system were purchased from InivoGen 
(San Diego, CA), polyethylene glycol (PEG)-8000 from Fisher Scientific (Pittsburgh, PA), 
SigmaUltra grade potassium chloride (99.0%) from Sigma Aldrich (St. Louis, MO), ACS reagent 
grade sodium citrate tribasic dehydrate (>99.0%) from Sigma Aldrich (St. Louis, MO), Human 
Fibrinogen (Plasminogen Depleted) and Human alpha Thrombin from Enzyme Research 
Laboratories (South Bend, IN), Aprotinin (from bovine lung) purchased from Sigma Aldrich (St. 
Louis, MO), Dulbecco's minimum essential medium (DMEM) and penicillin/streptomycin (P/S) 
from Invitrogen (Carlsbad, California) and characterized fetal bovine serum (FBS) from Hyclone 
(Logan, UT). HEK-293 cells were obtained from Stratagene (La Jolla, CA). This cell line was 
selected for use because they are easily transfected. All of the reagents were used as received 
without further modification or purification. 
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5.2.2 Lyophilization experiments 
5.2.2.1 Synthesis of NanoSiCaPs complexes 
Nanoparticles of silicate substituted calcium phosphate complexes with pDNA were synthesized 
as previously described (see Section 3.2.3). Briefly, 125.0µl of a calcium precursor solution, 
comprised of 6.25µl (1µg/µl) of pDNA (pSEAP), 15.53µl of 2M CaCl2 and 103.2µl of de-
ionized water was added to an equal volume of (125µl) of a HEPES Buffered Saline Solution 
(HBS), at pH 7.5. 8.3 mol% of Si-HBS was used for all experiments since this is the silicate 
concentration that yielded enhanced transfection as outlined in Chapter 3. The calcium precursor 
was added to the phosphate solution at an addition rate of 13.4µl/sec simultaneously as the 
phosphate precursor was vortexed at 500rpm using VWR digital mini vortexer (West Chester, 
PA). The addition rate and Ca/P ratio was optimized previously by our group and reported [67].  
5.2.2.2 Stability of NanoSiCaPs complexes 
For determining the influence of sucrose on stability of NanoSiCaPs complexes, 250µl of 
NanoSiCaPs dispersions were diluted with 250µl of 10%, 20% and 40% sucrose (w/v) solution 
to yield a final volume of 500µl of sucrose/NanoSiCaPs solution containing 5%, 10% and 20% 
sucrose (1:1 v/v). Samples without sucrose (0% sucrose) were prepared as per the protocol 
without any dilution with de-ionized water. Freshly prepared samples were used for in-vitro 
transfection and cell viability studies. 
5.2.2.3 Lyophilization of NanoSiCaPs complexes 
Transfection solutions lyophilized with sucrose were prepared by first diluting 250µl of 
NanoSiCaPs dispersions with 250ul of 20% sucrose (w/v) solution to yield a final 500µl of 
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sucrose/NanoSiCaPs solution of 10% (1:1 v/v). Samples lyophilized without sucrose were 
freeze-dried as-prepared without further dilution in de-ionized water (250ul). Additional sample 
of freshly prepared sample was allowed to age on bench-top at room temperature without any 
treatment. All the relevant samples were freeze-dried using the following protocol. First, the 
samples (either 250µl or 500µl) were placed in 2ml Serum Vials, Type I clear glass (Wheaton, 
Millville, NJ), covered with aluminum foil and were frozen at -80°C for 60 minutes. 
Approximately 5-6 holes were made in the aluminum foil to facilitate the sublimation of water 
during the lyophilization process. These holes were created using a 22G 1 1/2 needle (BD, 
Franklin Lakes, NJ). Second, the samples were lyophilized for 24 hours using a Labconco 
freeze-dryer (Model 4.5, Kansas City, MO). Third, following lyophilization, the aluminum foil 
covering the tubes was removed. The tubes were then capped and sealed under a glove bag 
purged with argon gas under sterile conditions. 
5.2.2.4 Long-term stability  
For stability testing, sealed lyophilized samples were stored either at 4°C or room temperature 
(approximately 25°C) for up to 3 weeks.   
5.2.2.5 In-vitro experiments 
Human embryonic kidney 293 cells (HEK-293) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 1% (v/v) Antibiotic–Antimycotic and 10% (v/v) fetal 
bovine serum (FBS), at 37 ºC with 10% CO2. Cells were maintained at sub confluency and 
passaged every 2-3 days. A day prior to transfection, cells were seeded in 12-well plates at a 
concentration of 1.63x105 cells/well. To study the influence of sucrose on transfection efficiency 
of NanoSiCaPs complexes, sucrose was mixed with aqueous suspension of freshly prepared 
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samples and 166.6µl of sucrose/NanoSiCaPs complexes were added per well. For samples, 
receiving no sucrose, 83.3µl of NanoSiCaPs were added per well. For transfection studies of the 
lyophilized NanoSiCaPs complexes, freeze-dried samples were taken at respective time points 
and reconstituted with 500µl of de-ionized water for samples lyophilized with sucrose and 250µl 
of de-ionized water for samples lyophilized without sucrose. Twenty-four hours post 
transfection, the gene expression was quantified using SEAP assay by mixing 20µl of growth 
media with 180µl of QUANTI-Blue solution in a 96-well plate for detection of the secreted 
embryonic alkaline phosphatase (SEAP) by transfected cells. Plate were incubated at 37ºC for 1 
hour and optical density (OD) was measured at 620-655nm using a microplate reader (Biotek, 
Synerge2). SEAP expression was normalized to total cell number using CyQuant cell 
proliferation assay kit (ThermoFisher) and represent as SEAP (nanograms) /104 cells. Cell 
viability was determined by MTT assay. 100 ml of MTT (5 mg/ml) was added to each well and 
incubated at 37 C for 4 hours. MTT containing medium was removed and 0.5 ml dimethyl 
sulfoxide (DMSO) was added to dissolve formazan crystals. The optical density of the solution 
was measured at 490 nm. 
5.2.2.6 Transmission electron microscopy of freshly prepared and lyophilized NanoSiCaPs 
Lyophilized samples were taken from storage at week 0, 1, 2 and 3, reconstituted with 500µl of 
de-ionized water. Two-three drops, approximately 15µl of freshly prepared and reconstituted 
NanoSiCaPs complexes were then added onto a carbon coated copper grid (Electron Microscopy 
Sciences, Hatfield, PA) and allowed to equilibrate for 3 min. The grids were then stained with 
UranyLess EM stain (Electron Microscopy Sciences, Hatfield, PA), rinsed in de-ionized water 
and allowed to air dry. Images were subsequently taken using a Hitachi 9500 transmission 
electron microscope (TEM) (Tokyo, Japan) set to an accelerating voltage of 100 kV. 
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5.2.3 Synthesis and assessment of fibrin gene delivery system 
5.2.3.1 Synthesis of Fibrin/NanoSiCaPs gels 
 In-vitro transfection studies assessing the influence of fibrinogen concentration, pDNA dose and 
aprotinin employed use of 96-well plate. For these experiments, 50µl or 70µl of fibrin gel were 
synthesized per well depending on the amount of NanoSiCaPs complexes (i.e. pDNA amount) 
incorporated in the gel. Fibrinogen and aprotinin were diluted in 20mM sodium citrate-HCl 
buffer (pH-7.4) to obtain the required concentrations (5, 10 and 20 mg/ml fibrinogen, and 
10µg/ml aprontinin) and thrombin (10U/ml) was accordingly diluted in a buffer comprising of 
50mM sodium citrate, 0.2M NaCl and 0.1% PEG-8000. For gel formation, fibrinogen was either 
used alone or mixed with aprotinin solution and added to the well of 96-well plate. NanoSiCaPs 
complexes were then freshly prepared as per the protocol (see Section 5.2.2.1) and subsequently 
mixed with thrombin. For gels containing 0.5µg pDNA (SEAP) per well, 20µl of NanoSiCaPs 
were used, and gels containing 1µg pDNA (SEAP) per well, 40µl of NanoSiCaPs complexes 
were used, such that the total reaction volume for both gels were 60µl per well.  Throughout the 
text, the concentrations of fibrinogen, thrombin, aprotinin and pDNA are given as the final 
concentration in the resultant gel after mixing and polymerization. NanoSiCaPs 
complexes/thrombin suspension was then added to well containing fibrinogen (with or without 
aprotinin) for fibrin gel formation for 30mins at room temperature. Control groups incorporated 
the gels synthesized with equal volume of the calcium precursor solution required for synthesis 
of 60µl gels, but without the pDNA or phosphate buffer (to prevent NanoSiCaPs formation).   
 91 
5.2.3.2 In-vitro experiments  
For in-vitro studies, 5.1x103 HEK-293 cells/per well were seeded on the gels with 100µl of 
growth media per well. To determine the transfection efficiency of the synthesized Fibrin-
NanoSiCaPs gels, the cells were plated on top of the gels and the amount of SEAP secreted by 
the transfected cells into medium was measured on day 2, day 4 and day 6. At the respective time 
points, 100µl of medium was replaced with fresh medium, and immediately frozen at 80 ºC until 
further analysis. To measure levels of SEAP, frozen media was thawed at 37 ºC and 20µl of 
media was mixed with 180µl of QUANTI-Blue solution in a 96-well plate for detection of SEAP 
by transfected cells. The plates were incubated at 37 ºC for 1 hour and optical density (OD) was 
measured at 620-655nm using a microplate reader (Biotek, Synerge2).  SEAP expression was 
normalized to total cell number using CyQUANT cell proliferation assay and represented as 
SEAP (nanograms) /104 cells.  
5.2.3.3 Fibrin-NanoSiCaPs formulation for 2-D and 3-D transfection 
For this part of the study, 300µl of gels were synthesized with 10mg/ml fibrinogen, 10U/ml 
thrombin and 10µg/ml of aprotinin containing 200µl of freshly prepared or lyophilized 
NanoSiCaPs (reconstituted prior to gel formation) (stored for up to 1 week). The volume of 
NanoSiCaPs complexes contained 5µg of pDNA-SEAP and pDNA-GFP. Two techniques of 
transfection were investigated in this study, namely 2-D and 3-D method of transfection (Figure 
5.1). For 2-D transfection, the gels were synthesized as described in previous section by mixing 
fibrinogen/ aprotinin solution with NanoSiCaPs/thrombin solution. 5x104 HEK-293 cells were 
plated on top of the gel. For 3-D method, 5x104 HEK-293 cells were suspended in 
NanoSiCaPs/thrombin solution and immediately mixed with fibrinogen/aprotinin solution for gel 
formation. After 30minutes of polymerization, growth media was added to the gels. Assessment 
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of transfection efficiency was carried out by quantifying the SEAP levels by transfected cell in 
the media as described in the previous section (see Section 5.2.3.2) and expressed as SEAP 
(nanograms)/104 cells. Qualitative assessment of transfection efficiency was carried out by 
visualizing GFP expression at specific time points using an inverted microscope with a 
fluorescence illuminator (CKX41, Olympus, Olympus America Inc.) and imaged with a digital 
camera (Olympus DP25 Microscope Camera, Olympus, Olympus America Inc.). Cell viability of 
2-D and 3-D transfection methods was determined by MTT assay. 100 ml of MTT (5 mg/ml) 
was added to each well and incubated at 37 ºC for 4 hours. MTT containing medium was 
removed and 0.5 ml dimethyl sulfoxide (DMSO) was added to dissolve formazan crystals. The 
optical density of the solution was measured at 490 nm. 
5.2.3.4 SEM imaging of Fibrin-NanoSiCaPs 
For this experiment, 300µl of fibrin gels were synthesized with freshly prepared and lyophilized 
NanoSiCaPs complexes. Following gel formation, the gels were dehydrated in the following 
graded series of alcohol solutions for 15minutes each: 30%, 50%, 70%, 90% and 100 % ethanol 
(3 times). The samples were then critically point dried from CO2 using a CPD 750 Emscope 
(Ashford, England). Once dried, the samples were sputter coated with palladium and were then 
imaged using a FEI-Apreo scanning electron microscope (ThermoFisher Scientific, Hillsboro, 
OR).  
5.2.4 Statistical analysis 
Statistical calculations were performed using GraphPad Prism software. The data was analyzed 
to test for significant (p<0.05) mean differences on in-vitro transfection efficiency, cell viability 
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and proliferation for different samples utilized in lyophilization and fibrin gel experiments using 
one-way analyses of variance (ANOVA). Experiments were run in duplicates and repeated three 
times with n=6. Each ANOVA on these response variables was significant at p<0.05. Post hoc 
tests for pair-wise differences and identification of homogeneous subgroups were also all 
performed using the Tukey HSD procedures and discussed in the results section for the relevant 
groups. 
5.3 RESULTS 
5.3.1 Influence of sucrose on NanoSiCaPs stability 
Since the mass ratio stabilizer/nanoparticle is important, the effect of different concentrations of 
sucrose on transfection ability of freshly prepared NanoSiCaPs was evaluated. NanoSiCaPs were 
freshly prepared on the day of transfection resulting in final volume of 5%, 10% and 20% 
sucrose (% w/v) in NanoSiCaPs suspension. SEAP expression 24-hour post transfection revealed 
that 10% sucrose resulted in the highest transfection of HEK-293 cells, 62±2.8 SEAP ng/104 
cells (Figure 5.2). Interestingly, the transfection efficiency of 10% sucrose containing 
NanoSiCaPs suspension was higher than the NanoSiCaPs suspension without any sucrose 
(49.5±2.3 SEAP ng/104 cells). This indicated the possibility of sucrose stabilizing the 
nanoparticles and inhibiting particle aggregation. However, at 20% sucrose concentration SEAP 
expression decreased in comparison to NanoSiCaPs suspension without sucrose, 39.3±2.6 SEAP 
ng/104 cells (Figure 5.2). MTT assay was performed to investigate the influence of sucrose 
concentration on cell metabolic activity. Cell viability was not significantly influenced by the 
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presence of sucrose in the NanoSiCaPs suspension, other than 20% sucrose sample that resulted 
in decrease in cell metabolic activity, ~80% viable cells (Figure 5.3). Decline in transfection 
efficiency for the 20% sucrose/NanoSiCaPs was attributed to the decrease in cell metabolic 
activity for these samples. 
 
 
 
 
Figure 5.2. Influence of sucrose on transfection efficiency of NanoSiCaPs complexes. 
In-vitro transfection of HEK-293 cells by NanoSiCaPs complexes with different concentrations of 
sucrose at 24h. SEAP expression is normalized to cell number, n=6. The data were reported ± SD, n=6 
(p<0.05). Post hoc analysis of the transfection profile showed statistical significance between groups, indicated 
by the asterisk (*) 
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Figure 5.3. Influence of sucrose/NanoSiCaPs complexes on cell metabolic activity. 
MTT assay measuring in-vitro cell metabolic activity of HEK-293 cells by NanoSiCaPs complexes 
with different concentrations of sucrose at 24h. Data is normalized to control group that received no 
treatment, n=6. The data were reported ± SD, n=6 (p<0.05). Post hoc analysis of the cell metabolic activity 
showed statistical significance between groups, indicated by the asterisk (*) 
 
 
 
5.3.2 Influence of lyophilization and storage on transfection efficiency of 
sucrose/NanoSiCaPs complexes 
The 10% sucrose/NanoSiCaPs complexes were lyophilized using a benchtop freeze-dryer. To 
ensure complete freezing, the samples were frozen to -80 ºC prior to freeze drying for 24-hours. 
Lyophilized samples, except the sample without any sucrose showed good cake appearance and 
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instantly dissolved in water. After reconstitution few large, undissolved particles were observed 
for the lyophilized samples without sucrose. This effect was more evident for NanoSiCaPs that 
were subjected to no lyophilization and stored at bench-top for 24-hours. Next, the influence of 
the lyophilization process on transfection efficiency of NanoSiCaPs was evaluated. SEAP 
expression of lyophilized 10% sucrose/NanoSiCaPs complexes, 44.11±3.4 SEAP ng/104 cells, 
was comparable to the SEAP expression observed for freshly prepared samples, 49.5±2.3 SEAP 
ng/104 cells (statistically not significant) (Figure 5.4). However, freeze-drying of NanoSiCaPs in 
the absence of sucrose had a detrimental effect on the reported gene expression resulting in a ~ 
40-fold reduction in SEAP expression, 1.2±1.4 SEAP ng/104 cells (Figure 5.4). This was also the 
case for NanoSiCaPs complexes that were subjected to aging for 24-hours (without 
lyophilization), 2.1±1.5 SEAP ng/104 cells (Figure 5.4). These results clearly indicated that the 
process of lyophilization in presence of sucrose does help in preserving the transfection ability of 
the NanoSiCaPs complexes. 
 97 
 
 
Figure 5.4. Effect of lyophilization on transfection efficiency of NanoSiCaPs complexes.  
In-vitro transfection of HEK-293 cells by NanoSiCaPs complexes at 24h. The nanoparticles were 
freshly prepared (no sucrose), prepared and stored at bench top for 24h (without sucrose), lyophilized 
(without sucrose) and lyophilized (with 10% sucrose). SEAP expression is normalized to cell number, n=6 (p 
< 0.05). The data were reported as mean ± SD.  
 
 
In order to evaluate the long-term stability and storage conditions, the sealed lyophilized 
formulations were stored at 4ºC and room temperature (R.T.) for up to 3 weeks. After 
reconstitution, the samples were analyzed for transfection efficiency. In-vitro transfection of 
HEK-293 cells with lyophilized formulations was not significantly changed by the storage 
temperature at all the time points, Figure 5.5 (statistically not significant). This indicated that 
NanoSiCaPs complexes lyophilized in with 10% sucrose can be stored under ambient conditions. 
However, decrease in transfection efficiency was observed for lyophilized samples stored at both 
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temperatures with prolonged storage. The stability of the lyophilized particles with prolonged 
storage is known to affect the transfection potential of the lyophilized non-viral vectors due to 
particle aggregation [117]. 
 
 
 
 
Figure 5.5. Effect of storage on transfection efficiency of lyophilized NanoSiCaPs complexes. 
NanoSiCaPs complexes were lyophilized with 10% sucrose, sealed and stored at 4ºC or room 
temperature (R.T.) for week 1, 2 and 3. In-vitro transfection of HEK-293 cells showing SEAP expression 24h 
post transfection by reconstituted NanoSiCaPs complexes. SEAP expression is normalized to cell number. 
The data were reported ± SD, n=6 (p<0.05). 
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5.3.3 TEM analysis of lyophilized NanoSiCaPs complexes 
TEM was used to qualitatively assess the particle size and extent of aggregation of 
sucrose/NanoSiCaPs with long-term storage at R.T. As shown in Figure 5.6a, Figure 5.6b and 
Figure 5.7a, sucrose/NanoSiCaPs complexes appeared to be spherical in nature with primary 
particle size ~100nm as seen earlier in Section 3.3.4 (Figure 3.10). However, the reconstituted 
samples at week 2 and week 3 displayed larger clumps of sucrose/NanoSiCaPs complexes 
demonstrating the effect of storage conditions on the stability of NanoSiCaPs (Figure 5.8a and 
Figure 5.8b).  
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Figure 5.6. TEM analysis of freshly prepared NanoSiCaPs complexes. 
(a) freshly prepared NanoSiCaPs without sucrose and (b) freshly prepared NanoSiCaPs with 10% 
sucrose (scale 500nm). 
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Figure 5.7. TEM analysis of lyophilized NanoSiCaPs complexes.  
(a) reconstituted after freeze-drying for 24h (no storage) and (b) reconstituted after 1-week storage at 
R.T. (scale 500nm). 
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Figure 5.8. TEM analysis of lyophilized NanoSiCaPs complexes (extended storage). 
(a) reconstituted after 2-weeks storage at R.T and (b) reconstituted after 3-weeks storage at R.T. 
(scale 500nm).  
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5.3.4 In-vitro transfection studies using Fibrin-NanoSiCaPs formualtion 
Transfection studies initially employed HEK-293 cells and 2-D transfection systems where cells 
were seeded on top of the synthesized Fibrin-NanoSiCaPs gels. We investigated the effect of 
different concentrations of fibrinogen on the gene transfer ability of various Fibrin-NanoSiCaPs 
formulations. Hydrogels were formed by mixing NanoSiCaPs with thrombin subsequently 
mixing it with fibrinogen solution (5, 10 or 20mg/ml fibrinogen). Gene expression for all the gel 
formulation was significantly low at day 2 but increased by day 4. In general, gene expression 
decreased with increase in fibrinogen concentration (Figure 5.9). Fibrinogen concentration of 
5mg/ml displayed peak expression at day 4, 19.8±1.1 SEAP ng/104 cells (Figure 5.9) but had 
completely degraded by day 6. The increased gene expression for gels synthesized with 
fibrinogen concentration of 10mg/ml at day 6, 24.18±1.8 SEAP ng/104 cells (Figure 5.9) reflects 
the balance between gel stability and cell proliferation. Since Fibrin-NanoSiCaPs gels 
synthesized with 10mg/ml fibrinogen displayed the highest gene expression for the duration of 
cell culture of 6 days, and retained their integrity for the cell culture period, all the subsequent 
studies were performed under this condition.  
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Figure 5.9. Effect of fibrinogen concentration on transfection efficiency. 
In-vitro transfection efficiency of HEK-293 cells showing SEAP expression at day 2, 4 and 6 by 
fibrin-NanoSiCaPs hydrogels synthesized using different concentrations of fibrinogen, 5mg/ml, 10mg/ml and 
20mg/ml. SEAP expression is normalized to cell number. Control group included gels synthesized with 
10mg/ml fibrinogen (without pDNA or NanoSiCaPs complexes). The data were reported ± SD, n=6 (p<0.05). 
Post hoc analysis of statistically significant groups indicated by asterisk (*). 
 
 
Next, we determined the amount of NanoSiCaPs (also refers to the amount of pDNA, see 
5.2.3.1) that resulted in the highest level of gene expression. Two different dosages of pDNA, 
0.5µg and 1µg of pDNA per well were tested. There was no difference in gene expression 
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between gels synthesized with two different dosages of pDNA, Figure 5.10 (statistically not 
significant). This was attributed to the rapid degradation and bulk release of NanoSiCaPs 
complexes from the fibrin network from both gels.  
 
 
 
 
Figure 5.10. Effect of pDNA doese on transfection efficiency. 
In-vitro transfection efficiency of HEK-293 cells showing SEAP expression at day 2, 4 and 6 by 
fibrin-NanoSiCaPs hydrogels synthesized using two amounts of pDNA corresponding to different amounts of 
NanoSiCaPs. SEAP expression is normalized to cell number. Control group included gels synthesized with 
10mg/ml fibrinogen (without pDNA and NanoSiCaPs). The data were reported ± SD, n=6 (p<0.05). 
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Subsequently we investigated if fibrin degradation can be controlled by incorporating a 
fibrinolytic inhibitor in Fibrin-NanoSiCaPs formulation and its influence on gene transfection 
abilities of synthesized gels. Aprotinin, a bovine pancreatic trypsin inhibitor was incorporated in 
the Fibrin-NanoSiCaPs formulation with both pDNA amounts of 0.5µg and 1µg. Addition of 
aprotinin at 10µg/ml decreased the gene expression for gels synthesized with two vector dosages 
(Figure 5.11). Interestingly, 0.5µg gels did not show any transfection until day 4 and gene 
expression for these gels was lower at all the time points in comparison to gels with 1µg pDNA 
(Figure 5.11). Incorporation of aprotinin delayed fibrin degradation and extended the transgene 
expression. These results also indicated that fibrin degradation was necessary for successful gene 
transfection. In addition, the gels synthesized with two doses of pDNA incorporating aprotinin 
had no detrimental effect on cellular proliferation as shown in Figure 5.12. 
 107 
 
 
Figure 5.11. Effect of fibrinolytic inhibitor on transfection efficiency. 
In-vitro transfection efficiency of HEK-293 cells showing SEAP expression at day 2, 4 and 6 by 
fibrin-NanoSiCaPs hydrogels synthesized incorporating 10µg/ml aprotinin. SEAP expression is normalized to 
cell number. Control group included gels synthesized with 10mg/ml fibrinogen (without pDNA and 
NanoSiCaPs complexes). The data were reported ± SD, n=6 (p<0.05). Post hoc analysis of statistically 
significant groups indicated by asterisk (*). 
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Figure 5.12. Cell proliferation analysis of Fibrin-NanoSiCaP gels. 
CyQuant assay measuring HEK-293 cell proliferation at day 2, 4 and 6. Data represented as fold 
change of control gel, statistically not significant (without pDNA and NanoSiCaPs). The data were reported ± 
SD, n=6 (p>0.05) 
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5.3.5 2-D vs 3-D fibrin gene delivery systems using lyophilized and freshly prepared 
NanoSiCaPs 
Finally, the use of lyophilized NanoSiCaPs for fibrin gel formulation was tested. Accordingly, 
NanoSiCaPs complexes were lyophilized in the presence of 10% sucrose and used within one 
week of storage for synthesizing the Fibrin-NanoSiCaPs gels, since this concentration of sucrose 
and storage conditions provided the highest transfection efficiency while preserving the particle 
stability. Additionally, two different models of gene delivery system, 2-D and 3-D models of 
transfection were employed (Figure 5.1). For these experiments, 300µl of gels were synthesized 
per well in a 24 well plate containing 200µl of freshly prepared or lyophilized NanoSiCaPs 
(corresponding to 5µg of pDNA coding for SEAP or GFP). The kinetics of gene expression for 
the fibrin gels synthesized with freshly prepared 2-D systems increased gradually from day 2 
(15.4±2.55 SEAP ng/104 cells), to a calculated ~2.4-fold increase observed on day 6 (36.3±2.68 
SEAP ng/104 cells and then decreasing by day 8 (18.9±1.4 SEAP ng/104 )cells as shown by the 
SEAP expression analysis in Figure 5.13 and qualitative assessment of GFP expression in Figure 
5.14a-d. Similar expression was observed for fibrin gels synthesized with lyophilized 
NanoSiCaPs that were stored no longer than 1 week and were reconstituted prior to gel 
formation. Gene expression for these gels for 2-D systems also increased gradually from day 2 
(10.9±4.36 SEAP ng/104 cells), to 2-fold increase on day 6 (20.7±3.94 SEAP ng/104 cells) and 
then decreasing by day 8 (18.7±2.18 SEAP ng/104) cells as shown by SEAP expression analysis 
in Figure 5.13 and qualitative assessment of GFP expression in Figure 5.14e-h.   
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Figure 5.13. 2-D method of transfection. 
In-vitro transfection efficiency of HEK-293 cells in 24-well plate showing SEAP expression at day 2, 4 
and 6.  300 µl of fibrin hydrogels were synthesized with freshly prepared and lyophilized NanoSiCaPs 
(reconstituted prior to gel formation). Cells were plated on top of the gels for 2-D method of transfection. 
SEAP expression is normalized to cell number. Control group included gels synthesized with 10mg/ml 
fibrinogen with empty NanoSiCaPs complexes (without pDNA). The data were reported ± SD, n=3 (p<0.05). 
Post hoc analysis of statistically significant groups indicated by asterisk (*). 
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Figure 5.14. Fluorescence microscopy images by 2-D transfection method. 
Qualitative assessment of GFP expression by HEK-293 cells in fibrin gels synthesized with: freshly 
prepared NanoSiCaPs on (a) day 2 (b) day 4 (c) day 6 and (d) day 8 (scale 200µm); lyophilized NanoSiCaPs 
(reconstituted prior to gel formation) on (e) day 2 (f) day 4 (g) day 6 and (h) day 8 (scale 200µm). 
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This duration of expression was subsequently compared to 3-D GDS with same quantities of 
pDNA. For 3-D GDS, there was a modest increase in gene expression during the cell culture 
period. As shown in Figure 5.15, 3-D GDS also had a later peak expression at day 8 (22.8±1.21 
SEAP ng/104 cells for fibrin gels prepared with freshly prepared NanoSiCaPs complexes), with a 
4-fold increase in gene expression from day 2 (5.66±1.60 SEAP ng/104 cells for fibrin gels 
prepared with freshly prepared NanoSiCaPs complexes). This was also qualitatively assessed by 
visualizing GFP expression using fluorescence microscopy, Figure 5.16a-d. Similar trend was 
observed for fibrin gels synthesized with lyophilized NanoSiCaPs, Figure 5.15 and Figure 5.16 
e-h. In general, 2-D GDS displayed higher levels of gene expression than 3-D GDS at all the 
time points. This is partly attributed to the fact that 2-D GDS displayed higher proportion of 
viable cells (~100% viable cells) at 24 h and 48 h time points as compared to 3-D GDS (~80% 
viable cells), Figure 5.17. Incorporation of 3-D system has been proposed earlier to extend 
transgene expression. In our study, we do observe that the 3-D GDS has a later onset of peak 
expression and other factors such as optimum number of cells encapsulated and incubation time 
of vectors with cells will also likely play a role in kinetics of gene expression which have not 
been investigated here. These results nevertheless, proved that the fibrin gels can be synthesized 
using lyophilized NanoSiCaPs and can achieve sustained gene expression up to 1 week.  
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Figure 5.15. 3-D method of transfection. 
In-vitro transfection efficiency of HEK-293 cells in 24-well plate showing SEAP expression at day 2, 4 
and 6.  300 µl of fibrin hydrogels were synthesized with freshly prepared and lyophilized NanoSiCaPs 
(reconstituted prior to gel formation). For 3-D method of transfection, 50,000 cells were suspended in 
NanoSiCaPs solution containing thrombin and immediately mixed with fibrinogen solution for gel formation. 
SEAP expression is normalized to cell number. Control group included gels synthesized with 10mg/ml 
fibrinogen with empty NanoSiCaPs complexes (without pDNA). The data were reported as mean ± SD (n=3). 
Post hoc analysis of statistically significant groups indicated by asterisk (*). 
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Figure 5.16. Fluorescence microscopy images by 3-D transfection method. 
Qualitative assessment of GFP expression by HEK-293 cells in fibrin gels synthesized with: freshly 
prepared NanoSiCaPs on (a) day 2 (b) day 4 (c) day 6 and (d) day 8 (scale 200µm); lyophilized NanoSiCaPs 
(reconstituted prior to gel formation) on (e) day 2 (f) day 4 (g) day 6 and (h) day 8 (scale 200µm). 
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Figure 5.17. Cell viability assay using 2-D and 3-D transfection methods. 
MTT assay measuring in-vitro cell metabolic activity of HEK-293 cells with 2-D and 3-D GDS at 24h 
and 48h. Control group included gels synthesized with 10mg/ml fibrinogen with empty NanoSiCaPs 
complexes (without pDNA). The data were reported as mean ± SD (n=3). Post hoc analysis of statistically 
significant groups indicated by asterisk (*). 
 
 
 
5.3.6 SEM imaging of Fibrin-NanoSiCaPs  
Scanning electron microscopy was used to assess the microstructure of the fibrin gels 
synthesized with freshly prepared and lyophilized NanoSiCaPs complexes. As evidenced in 
Figure 5.18a, Figure 5.18b, Figure 5.19a and Figure 5.19b there was no observable difference in 
the microstructure of the fibrin gels synthesized with freshly prepared or lyophilized 
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NanoSiCaPs (storage > 1 week). Figure 5.18b and Figure 5.19b, shows the primary particle size 
of encapsulated NanoSiCaPs complexes to be ~ 100nm. Specifically, SEM images of both gels 
shows homogenous dispersion of NanoSiCaPs complexes in the fibrin matrix with no evidence 
of significant aggregation.  
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Figure 5.18. SEM images of fibrin gels synthesized with freshly prepared NanoSiCaPs. 
(a) scale 2µm (b) scale 1µm. 
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Figure 5.19. SEM images of fibrin gels synthesized with lyophilized NanoSiCaPs. 
Fibrin gels synthesized with reconstituted lyophilized NanoSiCaPs after 1 week of storage (a) scale 
2µm (b) scale 1µm. 
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5.4 DISCUSSION 
The purpose of this study was to synthesize a 3-D gene delivery system (GDS) comprised of 
lyophilized NanoSiCaPs complexes and fibrin. The GDS was designed to facilitate sustained 
gene transfection of cells mediated by NanoSiCaPs complexes from the fibrin hydrogels. This 
was accomplished by achieving three major goals. First, developing a freeze-drying protocol for 
NanoSiCaPs by determining optimum sucrose concentration and storage conditions for 
lyophilized sucrose/NanoSiCaPs formulations. Second, synthesizing Fibrin-NanoSiCaPs 
hydrogels by determining the optimum fibrinogen and NanoSiCaPs concentrations. Third, 
determining the optimum cell transfection methodology, 2-D vs 3-D mediated via Fibrin-
NanoSiCaP gels.  
One of the major limitations preventing the use of CaP based vectors is the colloidal 
instability of these vectors, especially with prolonged storage under aqueous conditions [27]. In 
general, synthesis of CaP based gene delivery vectors rely on electrostatic interaction between 
the negatively charged pDNA and the calcium ions for condensation and subsequent particle 
formation by the addition of phosphates [27]. The surface charge of the synthesized complexes is 
approximately -20mV [67], and a minimum surface charge of ± 30mV has been shown to 
prevent particle aggregation [200]. Therefore, prolonged storage of synthesized NanoSiCaPs 
complexes in aqueous conditions results in aggregation. In addition, these complexes possess 
areas of charge neutrality which facilitate electrostatic interactions between the particles thus 
leading to particle aggregation [201]. This results in a decline in transfection efficiency of these 
complexes with prolonged storage as observed in the transfection experiments in this study 
utilizing aged samples (Figure 5.4). Overcoming this limitation was the motivation for the first 
part of this study to develop freeze dried formulation of NanoSiCaPs, which would enable both 
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withstanding the shipping and transportation related stresses and offer stability for long periods 
of time without exhibiting loss in transfection ability. In fact, several studies have shown that 
lyophilization, with the use of a lyoprotectant for example, a disaccharide, is an effective method 
for stabilizing lipid-DNA [113, 198] and polymer-DNA complexes [116, 197]. However, there 
are no reports to date, assessing the long-term stability of freeze-dried formulations comprising 
CaP and pDNA. Therefore, in our current work, we explored the possibility of lyophilizing 
NanoSiCaPs complexes, with the use of sucrose as a lyorprotectant, for achieving long-term 
stability of the nanoparticles.  
In agreement with previous studies for lipid- and polymer-based gene delivery vectors, 
our data demonstrated that the gene transfection ability of the NanoSiCaPs complexes can be 
maintained up to 3 weeks by freeze-drying these complexes with sucrose as a lyoprotectant 
(Figure 5.5) [117, 197, 199]. As mentioned in Section 5.2.2.3, all the lyophilized samples were 
first frozen at -80 ºC for 60 minutes prior to drying. This ensured that the samples were cooled 
below the freezing point of sucrose solution. Cooling the samples to -80oC guaranteed freezing 
of the sucrose/NanoSiCaPs suspension. It is believed that this process aided in the preservation 
of the “native” structure of the NanoSiCaPs particles with the sucrose preventing coalescence 
and as such helped to maintain the gene transfection abilities of the particles. Additionally, 
freeze-dried samples were sealed under inert conditions by purging argon gas in a glove bag as 
mentioned in the Section 5.2.2.4. In-vitro gene transfection of HEK-293 cells with 
sucrose/NanoSiCaPs formulations with different concentrations of sucrose (% weight/volume) 
revealed that sucrose can indeed stabilize NanoSiCaPs complexes in aqueous conditions 
resulting in increased SEAP expression for 10% sucrose formulation (Figure 5.2). This increase 
in gene expression is attributed to the colloidal stability conferred by sucrose molecules by 
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creation of H-bonds between hydroxyl groups on sucrose and the phosphate groups on pDNA 
[202] and/or NanoSiCaPs. In doing so, the sucrose molecules serve to sterically hinder the 
NanoSiCaPs complexes thus providing a medium for a stable dispersion of the NanoSiCaPs 
complexes. However, sucrose/NanoSiCaPs formulations with 20% sucrose concentrations 
resulted in reduced gene expression, which was attributed to the reduced cell metabolic activity 
for these samples, Figure 5.3. Reduced cell metabolic activity due to high sucrose concentration 
could be due to increasing level of tonicity resulting in cellular damage. In addition, high sucrose 
concentration can also influence the duration of the lyophilization cycle and significantly impact 
the production costs [111]. Our results indicated an optimum sucrose/NanoSiCaPs ratio offering 
particle stability while maintaining cell viability. Therefore, 10% sucrose was selected as the 
optimum concentration for lyophilization of NanoSiCaPs.  
In-vitro gene transfection studies of lyophilized NanoSiCaPs on HEK-293 cells showed 
that the process of freeze-drying did not affect the gene transfection ability of lyophilized 
NanoSiCaPs as compared to freshly prepared NanoSiCaPs, Figure 5.4. In contrast, samples 
lyophilized without sucrose and not lyophilized (aged) samples, resulted in 40-fold less SEAP 
expression. These results proved that sucrose can stabilize the NanoSiCaPs during the freeze-
drying process without inducing any loss in transfection abilities of these particles. However, 
transfection efficiency of lyophilized particles was independent of storage temperature as seen in 
our studies. Lyophilized sealed samples stored at 4 ºC and R.T. (under ambient conditions) had 
similar transfection efficiency at all time points, Figure 5.5 (statistically insignificant, p>0.05). 
Decrease in transfection efficiency with storage temperature is however, observed in other 
studies. It should also be noted that the decline in transfection efficiency noticed in these studies 
is observed at elevated temperatures, 40 ºC [117, 199]. In the current study, a steady decline in 
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transfection efficiency is observed with storage. Interestingly, even at week 3 the lyophilized 
sucrose/NanoSiCaPs formulations resulted in significant SEAP expression (Figure 5.5) as 
compared to samples lyophilized without sucrose and not lyophilized (aged) samples (Figure 
5.4). Decline in transfection efficiency with storage was believed to be caused by the presence of 
water content in the freeze-dried samples. The presence of moisture could be due to two reasons. 
First, the sucrose/NanoSiCaPs were lyophilized in a benchtop freeze-drier, which does not 
possess the capability of secondary drying, which is a crucial step to completely remove the 
residual moisture content from the freeze-dried samples. Second, even though, extreme 
precautions were taken while transporting the freeze-dried samples from the lyophilizer to the 
glove bag, it is possible that exposure to atmospheric conditions for brief period resulted in 
influx of water molecules into the freeze-dried samples. This could explain the decline in 
transfection efficiency of lyophilized sucrose/NanoSiCaPs formulations by week 3 (Figure 5.5). 
In general, an increase in water content can be critical for storage stability as it is associated with 
a decrease in the steric hindrance ultimately leading to aggregation of complexes in the freeze 
dried solid [113]. Future studies, incorporating a lyophilizer capable of secondary drying step 
and reducing the exposure of samples to atmospheric conditions can indeed solve this problem.  
In-vitro transfection results were further supported by the TEM analysis of reconstituted 
sucrose/NanoSiCaPs samples. Our data confirms the ability of sucrose to maintain the particle 
size of the lyophilized sucrose/NanoSiCaPs complexes. As confirmed by TEM analysis, 
sucrose/NanoSiCaPs samples yielded particle sizes that were same as positive control (freshly 
prepared NanoSiCaPs without sucrose), Figure 5.6a and Figure 5.6b. These particles were 
spherical in nature with primary particle size of ~100nm. However, with prolonged storage of 
sucrose/NanoSiCaPs samples there was an increase in particle aggregation, wherein week 3 
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samples mostly consisted of large clumps, Figure 5.8b. This explained the decline in transfection 
efficiency observed for these samples. Therefore, in the first part of the study, our results showed 
that both the particle size and transfection efficiency of the NanoSiCaPs complexes could be 
preserved for up to 1 week in storage under ambient conditions by freeze drying the 
nanoparticles with 10% sucrose.  
For the second part of this study, a 3-D gene delivery system (GDS) was synthesized 
comprising of NanoSiCaPs complexes and fibrin. In order to achieve that, current study focused 
on determining the optimum fibrinogen concentration, pDNA dose (i.e. amount of NanoSiCaPs 
complexes), incorporation of fibrinolytic agent, and evaluating two methods of in-vitro 
transfection (2-D vs 3-D) for generation of Fibrin-NanoSiCaPs formulation, as outlined in Figure 
5.1. Fibrin is used as a scaffold material for the current application even though it lacks the 
mechanical strength required for bone tissue engineering, as the long-term goal is development 
of a hybrid scaffold where a porous polymeric, ceramic or metallic scaffold with appropriate 
mechanical strength can be infiltrated with the synthesized Fibrin-NanoSiCaPs formulation.  
Initially, the aim was to investigate the role of fibrinogen concentration in gene 
transfection abilities of fibrin gels synthesized with freshly prepared NanoSiCaPs. The thrombin 
concentration was fixed at 10U/ml, since the concentration of thrombin plays a more significant 
role in reaction kinetics of the gel formation, whereas, fibrinogen concentration has been 
reported to affect cell proliferation, migration and differentiation [203-205]. In our assessment, 
SEAP expression was observed in all Fibrin-NanoSiCaPs gel formulations. A fibrinogen 
concentration of 10mg/ml provided an ideal balance between cell proliferation and gel stability 
for the duration of cell culture, 6 days (Figure 5.9). In general, fibrin gels with high fibrinogen 
concentrations (70-100mg/ml) have decreased cell proliferation and migration relative to gels 
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with low fibrinogen concentrations (10mg/ml) [203, 204]. Based on our transfection results and 
other reports in literature we selected the fibrinogen concentration of 10mg/ml for the synthesis 
of Fibrin-NanoSiCaP gels for all other subsequent studies.  
Interestingly, increasing pDNA amount (corresponding to respective amounts of 
NanoSiCaPs) in the fibrin gels did not yield higher gene transfection levels (Figure 5.10). This 
was attributed to the fact that Fibrin-NanoSiCaPs gels synthesized with 0.5µg and 1µg pDNA 
resulted in bulk release of complexes and did not induce sustained gene transfection for gels with 
high pDNA concentration. Notably, this has also been reported in other studies where increase in 
pDNA amount beyond a certain limit does not result in increase in transfection efficiency [194, 
206]. However, incorporation of 10µg/ml aprotinin, a fibrinolytic inhibitor delayed fibrin gel 
degradation and resulted in reduced gene expression for both pDNA doses (Figure 5.11). This 
experiment showed that fibrin degradation by target cells is necessary for gene delivery. 
Furthermore, the effect of pDNA dose on gene expression was more pronounced with use of 
aprotinin, where Fibrin-NanoSiCaPs gels with 1µg pDNA resulted in higher SEAP expression at 
all time points (Figure 5.11). Decrease in gene transfer efficiency with increase in aprotinin 
concentrations has been reported by Lei et al. [194], however in the current study only one 
concentration of aprotinin was investigated. These results indicated that sustained gene 
expression can be achieved by incorporating aprotinin in the synthesis of fibrin-NanoSiCaPs 
gels. Additionally, the synthesized Fibrin-NanoSiCaPs gels with aprotinin and two different 
doses of pDNA did not elicit any adverse effect on proliferation of HEK-293 cells (Figure 5.12).  
Transfection of cells using Fibrin-NanoSiCaPs gel formulations is critical to validate the 
activity of NanoSiCaPs following lyophilization, reconstitution in gel precursors and distribution 
in the 3-D environment of the hydrogel. Two primary models exist for in-vitro transfection using 
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hydrogel matrices: co-encapsulation of cells with vector in the gel precursor, i.e. 3-D, and initial 
separation of cells from the vector before gel formation, namely, 2-D.  While 3-D method of 
transfection provides a means of early detection of gene expression due to prior incubation of 
complexes with cells before gelation, homogenously dispersed cells may demonstrate limited 
migration and only have access to complexes initially distributed near the cells [207]. In contrast, 
2-D method of transfection involves separation of complexes from the cells before hydrogel 
formation and ensures that vector internalization occurs because of cell invasion, migration and 
hydrogel degradation [208]. In the current study, transfection of HEK-293 cells by 2-D method 
displayed higher SEAP expression at all the time points compared to the 3-D method. Reduced 
cell viability observed for HEK-293 cells cultured in 3-D system (Figure 5.17) can be one the 
predominant reason behind these lower levels of gene expression observed. However, other 
factors such as gel degradation due to cell invasion and migration are also likely to play a crucial 
role in dictating the gene transfection profile of the synthesized fibrin gels. For instance, the gene 
expression peaked at day 6 for 2-D method (Figure 5.13), whereas it peaked at day 8 for 3-D 
method (Figure 5.15). Notably, opposite results were observed by Lei et al. wherein 3-D 
transfection method displayed higher gene expression than 2-D methods [194]. Higher levels of 
gene expression in their study was also observed with increase in number of cells encapsulated in 
the fibrin gel. Additionally, the protocol utilized for 3-D transfection method utilized by Lei et al. 
incorporated incubation of lipoplexes with cell suspension for 15 minutes prior to gel formation 
[194], which may have resulted initial uptake of lipoplexes by the cells in suspension. In 
contrast, a similar study reported by Rieux et al. utilized 3-D method of transfection using fibrin-
lipoplex system, where lipoplexes were incubated for 30 minutes with cell suspension prior to 
gel formation [206]. Interestingly, the authors observed enhanced transfection for 2-D method as 
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compared to 3-D method. The authors explained this difference of transfection efficiency by 
vector-material interactions using confocal microscopy and concluded that transfection results 
for the 3-D model resulted primarily from the initial cell/vector interactions, rather than uptake 
by cells following encapsulation within the hydrogel [206]. Following these contrasting results 
using similar delivery vector used by Lei et al. and Rieux et al., and the results observed in our 
study clearly indicates that there is need for a more systematic study to be conducted to 
determine the influence of number of cells encapsulated in the hydrogel matrix and the 
mechanisms at work therein for clearly delineating the NanoSiCaPs transfection in 2-D vs. 3-D 
environments.  
The Fibrin-NanoSiCaPs gels exhibited the characteristic fibrillar structure in SEM 
micrographs. Gels synthesized with freshly prepared and lyophilized NanoSiCaPs displayed 
homogenous distribution of NanoSiCaPs complexes throughout the gel matrix. The morphology 
of the NanoSiCaPs complexes and the microstructure of the fibrin gels synthesized with either 
freshly prepared or lyophilized NanoSiCaPs appeared to be the same. Furthermore, NanoSiCaPs 
complexes in both the gels were non-aggregated and ~100nm in size. Taken together our results 
suggest that fibrin gels synthesized with lyophilized NanoSiCaPs complexes that yield sustained 
gene expression may indeed provide an effective platform for generation of gene delivery 
systems that has potential in bone tissue engineering.  
5.5 CONCLUSIONS 
In this assessment, we demonstrate use of gene delivery system using fibrin hydrogel as an 
encapsulation matrix to incorporate lyophilized NanoSiCaPs complexes. Our results showed that 
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NanoSiCaPs complexes lyophilized in the presence of sucrose can be stored for up to 1 week 
under ambient conditions without any change in both particle size and transfection efficiency as 
compared to freshly prepared samples. Preservation of transfection efficiency was only observed 
for nanoparticles lyophilized with sucrose. Embedding the NanoSiCaPs complexes within fibrin 
hydrogels allowed sustained gene expression for up to 1 week. Transfection mediated via Fibrin-
NanoSiCaPs dependent on fibrinogen and pDNA concentrations (NanoSiCaPs amount). The 
gene expression and gel degradation can be meticulously controlled by incorporation of 
fibrinolytic inhibitor, like aprotinin. Gene transfection using Fibrin-NanoSiCaPs gels also 
depends on the method of cell transfection, on the surface i.e. 2D or within the hydrogel i.e. 3D, 
suggesting that gene transfer may be a function of cell-matrix interaction and the local 
microenvironment. Fibrin gels synthesized with lyophilized NanoSiCaPs display similar 
transfection levels as compared to gels synthesized with freshly prepared NanoSiCaPs. These 
results are indeed promising as we show for the first time that lyophilization is an excellent 
method for not only stabilizing NanoSiCaPs complexes but also these complexes can be 
reconstituted for generation of fibrin gene delivery system that are promising tools providing 
scope for their use in bone tissue engineering and regenerative medicine applications.  
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6.0  CONCLUSIONS 
Calcium phosphate-based nanoparticles (CaP) have demonstrated great potential as non-viral 
gene delivery vectors. They are widely studied biomaterials for tissue engineering applications 
due to their biocompatibility and non-toxicity [83]. Their use in bone tissue engineering is 
especially attractive owing to their structural and compositional similarity to the mineralized 
tissue architecture of native bone. However, despite their widespread use, several issues 
regarding their colloidal stability, dissolution kinetics as well as the ability for prolonged storage 
have stymied their success and widespread use as a non-viral gene delivery vector. Therefore, in 
this dissertation we crafted strategies to address these limitations by altering the materials 
properties of the nanostructured calcium phosphates (NanoCaP) previously developed by our 
group [67]. We accordingly generated the substituted version called NanoSiCaPs exhibiting 
much improved gene transfection and subsequently developed novel methodologies to 
incorporate this enhanced version of NanoCaPs (NanoSiCaPs) in scaffolds commonly employed 
for bone tissue engineering.  
To further augment the transfection potential and thereby challenge the current accepted 
standard for CaP based non-viral gene delivery, we developed an enhanced version of 
NanoCaPs, by substituting known amounts of silicate ions for phosphate in the hydroxyapatite 
(HA) lattice, which we termed as NanoSiCaPs. Results discussed in the thesis indicated that in 
addition to excellent transfection levels exhibited by NanoCaPs alone in vitro, an additional 20-
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50% increase in gene transfection was observed for NanoSiCaPs (8.3-50 mol% silicate 
substitution) (Figure 3.8). This increase in transfection efficiency was attributed to its rapid 
dissolution properties (Figure 3.7) and it was believed that this aided in pDNA escape from 
lysosomal degradation. The silicate substitution also limited particle aggregation (Figure 3.10a-
d) which contributed to increase in transfection efficiencies of these complexes. However, high 
silicate substitution (>50 mol%) resulted in a drastic decline in transfection as the synthesized 
NanoSiCaPs deviated far from the characteristic hydroxyapatite phase formed as evidenced by 
the XRD and FTIR results (Figure 3.2 and Figure 3.4). Fundamental understanding of the 
influence of various amounts of silicate substitution on materials properties of the synthesized 
NanoSiCaPs utilized in this part of the study highlighted the importance of generating and 
maintaining a single phase of HA and its crucial role in pDNA binding and transfection.  
In addition to changing the materials properties of NanoSiCaPs, we developed and 
assessed them as functional vectors that can be incorporated on or within scaffolds for non-viral 
gene delivery. First, we focused on achieving surface mediated gene delivery from implant 
surfaces. It is hypothesized that bio-functionalized materials will offer a unique strategy to 
facilitate tissue regeneration and integration around implants. Our focus was thus to develop a 
methodology that can be easily applied to materials with different geometries and composition. 
To achieve that, we developed a novel and simple coating approach using NanoSiCaPs 
complexes that preferentially adsorbed onto titanium (Ti) substrates coated with poly (diallyl 
dimethylammonium chloride) (PDADMAC) (Figure 4.1). The generated Ti-polyelectrolyte 
NanoSiCaPs assemblies aptly called PNA, delivered pDNA to MC3T3-E1 cells, induced reporter 
gene expression, without eliciting any cytotoxicity, while simultaneously encouraging cell 
attachment on the substrate. Interestingly, the coated substrates that lacked NanoSiCaPs as a 
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delivery agent (pDNA only) did not result in efficient gene transfection (Figure 4.8), although 
these samples also supported cell attachment, without eliciting any cytotoxicity (Figure 4.9and 
Figure 4.10). This observation clearly suggested that it is indeed crucial to incorporate a 
transfecting agent in the coatings for successful delivery of pDNA to the cells and subsequently 
obtain the desired gene expression. Nevertheless, the reporter gene expression achieved from 
PNA could not be sustained for a week, since the peak gene expression was observed on day 3 
(Figure 4.8). It can also be construed that the adsorption of NanoSiCaPs complexes on Ti-
surfaces largely relies on the electrostatic interaction between the negatively charged 
NanoSiCaPs complexes and the positively charged polyelectrolyte, PDADMAC. This interaction 
while beneficial may have led to charge compensation with limited adsorption of the 
NanoSiCaPs complexes beyond a certain limit. Although, the methodology developed is simple, 
it lacked the desired control over the amount of NanoSiCaPs complexes needed for effective 
incorporation onto the substrate to achieve the sustained gene transfection warranting further 
studies. 
In order to overcome these challenges for the reasons discussed above, we developed a 
methodology that can provide precise control over the amount NanoSiCaPs complexes that can 
be incorporated in a scaffold. To achieve this goal, we focused on achieving gene delivery 
through the bulk of the scaffold, in contrast to the surface mediated gene delivery described in 
the previous approach. It was therefore, hypothesized that entrapping and distributing 
NanoSiCaPs complexes over a 3-D volume would serve two main purposes, First, the 
aggregation of NanoSiCaPs complexes can potentially be reduced or eliminated since the 
interactions between the individual NanoSiCaPs particles are less likely to occur if quickly 
incorporated in a hydrogel matrix after their formation. Second, the scaffold would serve as a 
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template for the infiltration, attachment and proliferation of cells, and subsequent transfection 
through the incorporated NanoSiCaPs complexes in the gel. To achieve that, we developed a 
gene delivery system comprised of NanoSiCaPs complexes and fibrin gels. For production of the 
Fibrin-NanoSiCaPs formulation, effect of fibrinogen concentration, vector dosage and 
incorporation of fibrinolytic inhibitor (aprotinin) on the gene transfer ability of the NanoSiCaPs 
complexes was investigated. We observed that gene transfection abilities of the gels can be 
meticulously controlled by modulating the fibrinogen concentration (Figure 5.9), vector dosage 
and incorporation of aprotinin (Figure 5.11). In our assessment, the Fibrin-NanoSiCaPs 
formulation synthesized in 96-well plates with 10mg/ml fibrinogen, 1µg pDNA and 10µg/ml 
aprotinin resulted in optimum gene expression during the in-vitro cell culture period of 6 days. 
Furthermore, for the Fibrin-NanoSiCaPs to be used in a clinical setting we also developed a 
lyophilization protocol for NanoSiCaPs complexes that would allow long-term storage of 
synthesized complexes.  
We hypothesized that development of a technique that could enable storage and shipment 
of pre-made NanoSiCaPs complexes would eliminate the need of having trained personnel for 
synthesizing the NanoSiCaPs complexes prior to its use. With respect to the fibrin gel study, 
reconstitution of the lyophilized NanoSiCaPs complexes prior to gel formation would further 
advance the feasibility of utilizing Fibrin-NanoSiCaPs formulations in a clinical setting. To 
achieve this goal, we developed a lyophilizing technique for preservation of NanoSiCaPs 
complexes in the presence of sucrose. In vitro transfection results of HEK-293 cells showed that 
10% sucrose (% weight/volume) can preserve transfection efficiency and particle morphology of 
NanoSiCaPs complexes through the freeze-drying process (Figure 5.4). Notably complexes that 
were lyophilized in the absences of sucrose and complexes that were aged (without 
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lyophilization) resulted in reduced transfection efficiency. Furthermore, lyophilized NanoSiCaPs 
complexes (with 10% sucrose) can be stored under ambient conditions for up to 1 week without 
any loss in transfection efficiency and observed measurable change in the particle size when 
compared to freshly prepared NanoSiCaPs complexes (Figure 5.5 and Figure 5.7). Finally, use of 
lyophilized NanoSiCaPs in the generation of fibrin gene delivery systems was assessed. The 
lyophilized NanoSiCaPs complexes (stored up to 1 week) were reconstituted for generation of 
fibrin hydrogels. In-vitro transfection efficiency employing 2-D and 3-D methods of transfection 
displayed similar gene expression profile in HEK-293 cells between gels synthesized with 
freshly prepared and lyophilized NanoSiCaPs complexes (Figure 5.13 and Figure 5.15). Similar 
microstructure of both gels was observed using SEM imaging (Figure 5.18 and Figure 5.19). 
These results thus indicated the successful generation of a gene delivery system comprised of 
fibrin gels that can be synthesized in the presence of reconstituted lyophilized NanoSiCaPs 
complexes and effectively displayed transfection ability comparable to the gels synthesized with 
freshly prepared NanoSiCaPs complexes.  
Overall in summary, the work presented in this dissertation describes the creation of next 
generation of CaP vectors, called NanoSiCaPs that display enhanced transfection abilities due to 
superior materials properties achieved through silicate substitution into the HA lattice. For these 
complexes to be utilized in bone tissue engineering applications, we also developed 
methodologies to achieve scaffold mediated non-viral gene delivery through NanoSiCaPs 
complexes. The methodologies developed in this study can achieve gene delivery both from the 
surfaces and the bulk of the scaffolds. Furthermore, sincere effort was made in crafting 
methodologies that would enable easy translation of these techniques towards a clinical setting. 
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However, further studies are clearly warranted to enable this seamless transition into the clinical 
setting which are discussed in the following chapter.  
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7.0  FUTURE DIRECTIONS 
In order to exploit the advantageous traits of NanoSiCaPs based non-viral vectors discussed in all 
the chapters discussed above which include, enhanced dissolution kinetics, high transfection 
efficiency and minimal cytotoxicity, additional strategies can be employed to exhibit higher 
therapeutic effect. One of the crucial intracellular barriers is the entry of pDNA to the nucleus of 
the cells. pDNA once released from the endosome must make its pathway into the cell nucleus 
for successful transcription and subsequent protein expression in the cytosol. This barrier as is 
ubiquitously known poses a significant challenge for achieving successful gene transfection of 
primary stem cells and terminally differentiated cells. Therefore, the use of messenger RNA 
(mRNA) can be an attractive strategy over the pDNA delivery discussed in this dissertation, 
since mRNA does not need to enter the nucleus of the cells to be functional, thereby being 
effective for both dividing and non-diving cells [209]. In theory, the formation of NanoSiCaPs-
mRNA complexes should be straight forward since it will employ the same principle of 
DNA/RNA condensation in the presence of calcium ions and subsequent precipitation in the 
presence of phosphate and silicate ions, as observed for the NanoSiCaPs-pDNA complex 
formation. Systemic studies would be required for chemical modification of the mRNA 
complexes for achieving higher stability and their subsequent use in the generation of 
NanoSiCaPs-mRNA complexes. 
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To further prove the efficacy and feasibility of polyelectrolyte NanoSiCaPs assembly 
(PNA), the fabrication methodology should be applied to other ceramic, metallic and polymeric 
biomaterials. Since the PNA methodology can be achieved in 30 minutes, it opens up the 
possibilities to achieve similar surface modifications on degradable substrates in addition to inert 
substrates. This would enable the creation of PNA on degradable metallic implants such as 
magnesium-based alloys that exploits the useful traits of biodegradability and mechanical 
strength for orthopedic applications. Additionally, to exploit the advantageous traits of 
nanoceramic coating obtained on the surfaces through PNA generation, such as creation of 
rougher surfaces in the nanoscale range, additional research would be required to understand the 
influence of these topographies on the differentiation of mesenchymal stem cells (MSCs) and/or 
osteoblasts. Osteogenic differentiation of hMSCs is guided by various physical and biochemical 
factors. Controlled nanotopographies created on the biomaterial surfaces, such as pits, grooves, 
rods, and pores, have already been shown to regulate bone cell adhesion, spreading, proliferation, 
and differentiation [210]. Therefore, it is important to study the effect of nanoceramic coating on 
the osteoconductive properties of the modified surfaces by carrying out gene expression analysis 
of the relevant cells attached to the substrates.  
Fibrin gels synthesized with lyophilized NanoSiCaPs complexes displayed encouraging 
results in the current study. Based on the results observed in the current study there is clearly 
scope for further development of the synthesized GDS by developing a systematic study, to 
determine the influence of number of cells encapsulated in the hydrogel matrix for the 3-D 
method of transfection as well as investigate the optimum incubation time of NanoSiCaPs with 
cells prior to gel formation. These studies will help in understanding the mechanisms at work 
therein for clearly delineating the NanoSiCaPs transfection in both 2-D vs. 3-D environments. 
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The immediate next step for showcasing its efficacy for bone tissue engineering applications 
would be to utilize the gel formulation for infiltration of porous ceramic, polymeric or metallic 
bone implant materials. Additionally, 3-D printed scaffolds with desired dimensions can be 
effectively utilized for the generation of functional gel-implant hybrid scaffolds.  
Finally, for any biomaterials to be clinically effective, it needs to be tested in relevant 
animal models proving its efficacy. The synthesized NanoSiCaPs, lyophilized NanoSiCaPs, 
PNA, and Fibrin-NanoSiCaPs formulations should be tested in relevant animal models with 
specific gene of interest to show the efficacy of this gene delivery vector. Ideally first,  the 
studies should incorporate testing these scaffolds for the induction of ectopic bone formation, 
since this is an effective way to demonstrate bone inducing capability of vector/scaffolds [20]. 
Additionally, attention should be given to the animal models utilized for testing these scaffolds. 
Currently, most of the in-vivo experiments conducted for testing synthetic biomaterials utilize 
young rodent models. However, orthopedic biomaterials are implanted more frequently in 
geriatric patients suffering from other major health problems which interfere with the natural 
healing response around implants. Aging is also associated with up-regulation of ROS, 
inflammatory cytokines, and accompanying tissue damage. Therefore, it is crucial to establish 
new in-vitro and in-vivo experiments to test the efficacy of fabricated scaffolds. Establishing 
suitable animal models that can closely mimic the aging-induced deterioration of immune system 
and stem cells observed in humans would not only lead to successful clinical outcomes, but also 
reduce the burden on healthcare costs.  
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APPENDIX A 
MISCELLANEOUS EXPERIMENTS FOR CHAPTER 3: IN-VITRO TRASNFECTION 
EFFICIENCY OF NANOSICAPS IN COMPARISON TO OTHER COMMERCIAL 
NON-VIRAL VECTORS 
A.1 SUMMARY 
In Chapter 3.0 , we investigated the influence of silicate ion substitution on NanoCaPs gene 
transfection abilities. 8.3 mol% Si substitution, termed as NanoSiCaPs displayed the highest 
transfection efficiency and was selected as the gene delivery agent for subsequent studies. We 
also compared the transfection efficiency of NanoSiCaPs (with 8.3 mol% substitution) with a 
few commercially available non-viral agents. In addition, influence of non-viral agents on cell 
metabolic activity was also assessed.  
A.2 METHODS 
For this experiment, NIH-3T3 fibroblasts cells were used to determine the transfection efficiency 
and cell viability. For the transient transfection experiments, the cells were seeded in 12-well 
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plates at cell-density of about 1.0 x 105 cells per well. The gWiz GFP was complexed with 
NanoSiCaPs as described above in Section 3.2.3, and immediately transferred drop by drop into 
each well. Commercially available non-viral agents used for this study included polymer-based 
transfection reagents namely, X-tremeGENE 9 and X-tremeGENE HP, and cationic-lipid based 
reagent, Lipofectamine 2000. The transfection complexes were made by using optimum 
complex:pDNA ratio (1:1) as per manufactures protocol so that each well received same 
amounts of pDNA as used for NanoSiCaPs complexes i.e.  2.11µg gWiz GFP pDNA per well. 
The complexes were prepared in Opti-MEM Reduced serum media and incubated for 5 minutes 
for complex formation. The complexes were incubated with the cells for 24 hours after which 
transfection efficiency was measured by counting the GFP positive cells using the Accuri C6 
Flow Cytometer (n=3). Cell metabolic activity was measured using MTT assay as described in 
Section 5.2.2.5(n=3).  
A.3 RESULTS AND DISCUSSION 
As shown in Figure A. 1, transfection efficiency of X-tremeGene HP and Lipofectamine 2000 
was comparable~ 55% GFP expression, whereas NanoSiCaPs displayed a lower transfection 
efficiency than these samples with 47% GFP positive cells. On the other hand, X-tremeGene 9 
had the lowest transfection efficiency with only 13% GFP positive cells. Commercially available 
transfection reagents undergo self-assembly with negatively charged pDNA to from particles or 
complexes that are small enough for cellular uptake. Due to the positive charge of the complexes 
for polymer-based and cationic lipid-based reagents, the synthesized particles are able to interact 
with cellular membranes which is negatively charged, and thus be internalized by cells [211]. 
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However, due to the high surface charge these complexes are known to cause cytotoxic effects 
[212, 213], which was also seen in this study. MTT assay measuring cell metabolic activity did 
show cytotoxic effect of these complexes on NIH-3T3 fibroblast cells, Figure A. 2. Cells treated 
with NanoSiCaPs complexes displayed highest viability with 83% viable cells, followed by X-
tremeGENE 9 with 80% viable cells. In contrast, X-tremeGENE HP and Lipofectamine 2000 
had only about 42% viable cells. Even though the gene transfection efficiency of these samples 
were higher than NanoSiCaPs complexes, the induced cytotoxicity observed for these complexes 
was significant. These results suggested that, depending on the type of tissue engineering 
application, choice of non-viral reagent will play a crucial role in determining the ultimate 
outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A. 1. Transfection efficiency of NanoSiCaPs and commercial non-viral agents. 
Flow cytometry analysis (at 24hours) of GFP transfected NIH-3T3 cells by different transfection 
reagents. The control used for the flow analysis included GFP negative cells receiving no treatment. The data 
were reported ± SD, n=3 (p<0.05). Post hoc analysis of the cell metabolic activity showed statistical 
significance between groups, indicated by the asterisk (*). 
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Figure A. 2. MTT assay showing cell metabolic activity. 
MTT assay measuring in-vitro cell metabolic activity of NIH-3T3 cells by different transfection 
reagents at 24h. Data is normalized to control group that received no treatment. The data were reported ± 
SD, n=3 (p<0.05). Post hoc analysis of the cell metabolic activity showed statistical significance between 
groups, indicated by the asterisk (*). 
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